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CHAPTER I 
 
INTRODUCTION 
 
 A number of enzymes that catalyze essential physiological processes also have the 
capacity to damage the genome during the course of their normal activities. For example, 
while the cell requires DNA polymerases to copy the genetic material, these enzymes 
insert an incorrect base approximately every 10
7
 nucleotides (1). Consequently, in the 
absence of mismatch repair pathways, human DNA polymerases would generate several 
hundred mutations every round of cell division. Furthermore, while DNA glycosylases 
initiate base excision repair pathways, these enzymes can convert innocuous lesions to 
abasic sites with far greater mutagenic potential (2). Finally, while cytochrome P450 
enzymes play critical roles in detoxification pathways, they sometimes convert inert 
xenobiotic chemicals to compounds with mutagenic properties (3). 
 Of all the enzymes required to sustain cellular growth, topoisomerase II is one of the 
most dangerous (4-8). As discussed below, this enzyme unwinds, unknots, and untangles 
the genetic material by generating transient double-stranded breaks in DNA (8-12). 
Although the cell cannot survive without topoisomerase II, the strand breaks that the 
enzyme generates have the potential to trigger cell death pathways or chromosomal 
translocations (8,13).  
 
 
 
2 
DNA Topology 
 The existence of topoisomerases is necessitated by the structure of the double helix. 
Each human cell contains ~2 meters of DNA that are compacted into a nucleus that is 
~10 μm in diameter (14,15). Because the genetic material is anchored to the chromosome 
scaffold and the two strands of the double helix are plectonemically coiled, accessing the 
genome is a complex topological challenge (11,12,16-18).  
 Topological properties of DNA are those that can only be changed when the double 
helix is broken (12). The mathematical aspects of DNA topology involve three key 
concepts: twist (Tw), writhe (Wr), and linking number (Lk) (12,19-21). Twist represents 
the total number of double helical turns in a given segment of DNA. By convention, the 
right-handed twist of the Watson-Crick structure is assigned a positive value. Writhe is a 
property of the spatial course of the DNA and is defined as the number of times the 
double helix crosses itself if the molecule is projected in two dimensions (Figure 1). The 
helix-helix crossovers (i.e., nodes) are assigned a positive or negative value based on the 
orientation (i.e., handedness) of the DNA axis. The numerical term that describes the sum 
of the twist and the writhe is called the linking number, which represents the total linking 
within a DNA molecule. Mathematically, these properties of DNA can be expressed as:  
Lk = Tw + Wr. 
 Two critical points need to be emphasized. First, as discussed above, as long as the 
ends of DNA are fixed in space, Lk is an invariant value that cannot be changed without 
opening the system (i.e., breaking the DNA chain). Second, in the absence of knots or 
tangles, Tw and Wr are (at least mathematically) fluid values that can be interconverted.
3 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Topological relationships within DNA. DNA molecules are shown as circular 
ribbons for simplicity. Top: DNA with no torsional stress is referred to as “relaxed.” 
Underwinding or overwinding DNA results in negative (–) or positive (+) supercoils, 
respectively. The directionality of the DNA is shown by internal arrowheads in the 
negatively supercoiled [(–)SC] molecule. Supercoils are shown as writhes (DNA 
crossovers or nodes) for visual ease, but it should be noted that supercoils can be 
interconverted from writhes to twists. By convention, each writhe (denoted by the 
crossing of one DNA segment over another segment) is given an integral value of –1 or 
+1. Middle: Tracing the direction of the DNA, the sign of the node is assigned based on 
the direction of movement required to align the front segment of DNA with the back 
segment using a rotation of <180º. Negative DNA writhes are represented by crossovers 
in which the front segment must be rotated in a clockwise manner to align it with the 
back segment, while positive writhes require a counterclockwise rotation. Bottom: 
Intramolecular knots and intermolecular tangles also form in DNA. 
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The classic example for this interconversion is a telephone cord (12,19-21). In its 
“native” unstretched configuration, the cord is coiled  (i.e., writhes about itself), but there 
is no visible twisting of the cord. If the cord is stretched, all of the coiling is lost and the 
cord is visibly twisted. 
 With the above mathematics in mind, think of the human genome as a series of 46 
very long double-stranded ropes in which the two strands of each rope are 
plectonemically coiled about one another. Using this analogy, two aspects of topology 
can be envisioned. The first deals with topological relationships between the two strands 
of the double helix. DNA in the Watson-Crick structure is not under torsional stress. 
Hence, we refer to this DNA as “relaxed.” By definition, a relaxed circular DNA 
molecule that is 1050 bp in length should have an Lk = +100 (1050 bp ÷ 10.5 bp/turn). 
However, relaxed DNA does not exist in nature. In all living systems, from bacteria to 
humans, DNA is globally underwound by ~6% (12,19-21). This means that for every 
~1,050 base pairs, there are ~94 turns of the helix as opposed to the expected ~100 turns. 
The term Lk (linking difference) is used to describe this difference. Lk is equal to the 
actual linking number of a molecule minus the linking number of the DNA if it were 
completely relaxed (Lk0). Hence for the above example, Lk = Lk(94) – Lk0(100) = -6.  
 DNA underwinding or overwinding induces torsional stress within the molecule. If 
this stress is allowed to freely distribute along the nucleic acid, some of it will be 
converted to axial stress. This redistribution causes the molecule to writhe about itself 
forming superhelical twists (Figure 1). This is why DNA that is under torsional stress is 
referred to as supercoiled (12,19-21). Underwound and overwound molecules are called 
negatively and positively supercoiled, respectively.  
5 
 The term Lk described above is dependent on the length of the DNA. In order to 
compare levels of supercoiling in molecules of different sizes, the term  (specific linking 
difference or more commonly, superhelical density) is utilized.  is independent of DNA 
length and can be calculated using the equation:  
 = Lk ÷ Lk0. 
Thus, for the example discussed above,  = Lk(-6) ÷ Lk0(100) = –0.06. The  value for 
underwound DNA is always negative and for overwound DNA is always positive. 
However, negatively supercoiled DNA still has a positive Lk value.  
 The fact that DNA in vivo is globally underwound (i.e., negatively supercoiled) is 
important because duplex DNA is merely the storage form for the genetic information 
(12,19-21). To replicate or express this information, the two strands of DNA must be 
separated. Since global underwinding of the genome imparts increased single-stranded 
character to the double helix, negative supercoiling greatly facilitates strand separation 
(12,16-18).  
 While negative supercoiling promotes many nucleic acid processes, DNA 
overwinding (i.e., positive supercoiling) inhibits them. The linear movement of tracking 
enzymes, such as helicases and polymerases, compresses the turns of the double helix 
into a shorter region (Figure 2) (12,19-21). Consequently, the double helix becomes 
increasingly overwound ahead of tracking systems. The positive supercoiling that results 
makes it more difficult to open the two strands of the double helix and ultimately blocks 
essential nucleic acid processes (10,12,16-18). 
 The second aspect of DNA topology deals with relationships between separate DNA 
segments. Intramolecular knots (formed within the same DNA molecule) are generated 
6 
during recombination, and intermolecular tangles (formed between daughter DNA 
molecules) are produced during replication (Figure 2) (8,10,12,17). DNA knots block 
essential nucleic acid processes because they make it impossible to separate the two 
strands of the double helix. Moreover, tangled DNA molecules cannot be segregated 
during mitosis or meiosis (8,10,12,17). Consequently, DNA knots and tangles can be 
lethal to cells if they are not resolved. 
 
DNA Topoisomerases 
 The topological state of the genetic material is regulated by enzymes known as 
topoisomerases (8,10,11,22,23). Topoisomerases are required for the survival of all 
organisms and alter DNA topology by generating transient breaks in the double helix 
(8,10,11,22,23). There are two major classes of topoisomerases, type I and type II, that 
are distinguished by the number of DNA strands that they cleave and the mechanism by 
which they alter the topological properties of the genetic material (8,10,11,22,23).  
 Eukaryotic type I topoisomerases are monomeric enzymes that require no high-
energy cofactor (11,22,24). Type I enzymes are organized into two subclasses: type IA 
and type IB. These enzymes alter topology by creating transient single-stranded breaks in 
the DNA, followed by passage of the opposite intact strand through the break (type IA) or 
by controlled rotation of the helix around the break (type IB) (11,22,24). Type IA 
topoisomerases need divalent metal ions for DNA scission and attach covalently to the 
5’-terminal phosphate of the DNA (11,22,24). In contrast, type IB enzymes do not 
require divalent metal ions and covalently link to the 3’-terminal phosphate (11,22,24). 
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Figure 2: Nuclear processes induce changes in DNA topology. DNA replication is used 
as an example. Although chromosomal DNA is globally underwound in all cells, the 
movement of DNA tracking systems generates positive supercoils. As shown in A, 
chromosomal DNA ends are tethered to membranes or the chromosome scaffold 
(represented by the red spheres) and are unable to rotate. Therefore, the linear movement 
of tracking systems (such as the replication machinery represented by the yellow bars) 
through the immobilized double helix compresses the turns into a shorter segment of the 
genetic material and induces acute overwinding (i.e. positive supercoiling) ahead of the 
fork (B). In addition, the compensatory underwinding (i.e. negative supercoiling) behind 
the replication machinery allows some of the torsional stress that accumulates in the 
prereplicated DNA to be translated to the newly replicated daughter molecules in the 
form of precatenanes (C). If these precatenanes are not resolved, they ultimately lead to 
the formation of intertwined (i.e., tangled) duplex daughter chromosomes. Adapted from 
Ref. (10). 
Replication 
Replication 
(+) 
Replication 
(+) Precatenanes 
A 
B
C
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As a result of their reaction mechanism, type I topoisomerases can modulate DNA under- 
and overwinding, but cannot remove knots or tangles from duplex DNA (22,24,25).  
 Eukaryotic type II topoisomerases function as homodimers and require divalent 
metal ions and ATP for complete catalytic activity (5,8,26-28). These enzymes 
interconvert different topological forms of DNA by a “double-stranded DNA passage 
reaction” that can be separated into a number of discrete steps (5,8,26-28). Briefly, type II 
topoisomerases 1) bind two separate segments of DNA, 2) create a double-stranded break 
in one of the segments, 3) translocate the second DNA segment through the cleaved 
nucleic acid “gate,” 4) rejoin (i.e., ligate) the cleaved DNA, 5) release the translocated 
segment through a gate in the protein, and 6) close the protein gate and regain the ability 
to start a new round of catalysis (5,26-33). Because of their double-stranded DNA 
passage mechanism, type II topoisomerases can modulate DNA supercoiling and also can 
resolve DNA knots and tangles. 
 
Topoisomerase II 
 Lower eukaryotes and invertebrates encode only a single type II topoisomerase, 
known as topoisomerase II (34-37). In contrast, vertebrate species encode two closely 
related isoforms of the enzyme, topoisomerase II and topoisomerase II. These isoforms 
differ in their protomer molecular masses (170 vs. 180 kDa, respectively) and are 
encoded by separate genes (8,10,22,28,38-44). Topoisomerase II and topoisomerase II 
display a high degree (~70%) of amino acid sequence identity and similar enzymological 
characteristics. One notable difference between the two isoforms is that topoisomerase 
II relaxes (i.e., removes) positive superhelical twists ~10 times faster than it does 
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negative in vitro, while the  isoform is unable to distinguish the geometry of DNA 
supercoils during DNA relaxation (45).  
 Topoisomerase II and topoisomerase II have distinct patterns of expression and 
separate cellular functions. Topoisomerase II is essential for the survival of proliferating 
cells, and protein levels rise dramatically during periods of cell growth (46-49). The 
enzyme is further regulated over the cell cycle, with protein concentrations peaking in 
G2/M (48,50,51). Topoisomerase II is associated with replication forks and remains 
tightly bound to chromosomes during mitosis (9,49,52-54). Thus, it is believed to be the 
isoform that functions in growth-related processes, such as DNA replication and 
chromosome segregation (10,49).  
 Topoisomerase II is dispensable at the cellular level (38,42) but appears to be 
required for proper neural development (52,55). Expression of topoisomerase II is 
independent of proliferative status and cell cycle, and the enzyme dissociates from 
chromosomes during mitosis (42,52,56). Topoisomerase II cannot compensate for the 
loss of topoisomerase II in mammalian cells, suggesting that these two isoforms do not 
play redundant roles in replicative processes (42,49,57,58). Although the physiological 
functions of topoisomerase II have yet to be defined, recent evidence indicates 
involvement in the transcription of hormonally- or developmentally-regulated genes 
(58,59).  
 Much of what we understand regarding the mechanism of action of type II enzymes 
comes from experiments with topoisomerase II from species that express only a single 
form of the protein. Consequently, eukaryotic type II topoisomerases will be referred to 
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collectively as topoisomerase II, unless the properties being discussed are specific to 
either the  or  isoform.  
 
Topoisomerase II-Mediated DNA Cleavage and Ligation 
 The ability of topoisomerase II to cleave and ligate DNA is central to all of its 
catalytic functions (5,8,11,27). All topoisomerases utilize active site tyrosyl residues to 
mediate DNA cleavage and ligation. Since type II enzymes cut both strands of the double 
helix, each protomer subunit contains one of these residues (Tyr805 and Tyr821 in 
human topoisomerase II and topoisomerase II, respectively). 
 Topoisomerase II initiates DNA cleavage by the nucleophilic attack of the active site 
tyrosine on the phosphate of the nucleic acid backbone (Figure 3) (11,23,26,27). The 
resulting transesterification reaction results in the formation of a covalent phosphotyrosyl 
bond that links the protein to the newly generated 5’-terminus of the DNA chain. It also 
generates a 3’-hydroxyl moiety on the opposite terminus of the cleaved strand. The 
scissile bonds on the two strands of the double helix are staggered and are located across 
the major groove from one another. Thus, topoisomerase II generates cleaved DNA 
molecules with 4-base 5’-single-stranded cohesive ends, each of which is covalently 
linked to a separate protomer subunit of the enzyme (60-62).  
 The covalent enzyme-DNA linkage plays two important roles in the topoisomerase 
II reaction mechanism. First, it conserves the bond energy of the sugar-phosphate DNA 
backbone. Second, because it does not allow the cleaved DNA chain to dissociate from 
the enzyme, the protein-DNA linkage maintains the integrity of the genetic material 
during the cleavage event (11,23,26,27). The covalent topoisomerase II-cleaved DNA  
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Figure 3: Double-stranded DNA cleavage mediated by topoisomerase II. Scissile bonds 
are located four bases apart on opposite strands of the double helix. During cleavage, the 
active site tyrosine residue of each topoisomerase II protomer subunit becomes 
covalently linked to the newly generated 5’-terminal phosphate moiety on each strand.  
This covalent linkage preserves the energy of the sugar-phosphate DNA backbone. The 
newly generated 3’-hydroxyl group interacts with topoisomerase II in a non-covalent 
fashion. Ligation represents the reverse of this process and leaves the DNA product 
chemically unchanged from the initial substrate.  
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reaction intermediate is referred to as the “cleavage complex” and is critical for the 
pharmacological activities of the enzyme, which are discussed later in this chapter.  
 Although topoisomerase II acts globally, it cleaves DNA at preferred sites (63). The 
consensus sequence for cleavage is weak, and many sites of action do not conform to it 
(63). Ultimately, the mechanism by which topoisomerase II selects DNA sites is not 
apparent, and it is nearly impossible to predict de novo whether a given DNA sequence 
will support scission. Most likely, the specificity of topoisomerase II-mediated cleavage 
is determined by the local structure, flexibility, or malleability of the DNA that 
accompanies the sequence, as opposed to a direct recognition of the bases that comprise 
that sequence (64). 
 Beyond the nucleophilic attack of the active site tyrosine on the DNA backbone, the 
details of topoisomerase II-mediated DNA cleavage are not well defined. However, 
information regarding the roles of specific amino acid residues comes from structural 
studies on the catalytic core of yeast topoisomerase II generated in the absence of DNA 
or in a non-covalent complex with its nucleic acid substrate (27,65).  
 The DNA cleavage reaction requires a divalent metal ion (5,30,66,67). Mg
2+
 appears 
to fulfill this function in vivo (5). A two-metal-ion mechanism for DNA cleavage 
mediated by the bacterial type II topoisomerase, DNA gyrase, has been proposed (68). 
This mechanism was proposed based on structural homology (to other enzymes) and 
limited biochemical evidence (68). However, it has not been demonstrated whether this 
mechanism also applies to the human type II topoisomerases. 
 Topoisomerase II-DNA cleavage complexes normally are short-lived and readily 
reversible (5,8,69), and the DNA cleavage/ligation equilibrium of the enzyme greatly 
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favors ligation (5,8,11,23,26,27,70). Under equilibrium conditions, ~0.5–1% of 
topoisomerase II in a DNA scission reaction mixture exists as a cleavage complex (60-
62,71). Furthermore, when Mg
2+
 is utilized as the divalent metal ion, ~1/2–3/4 of the 
complexes contain double-stranded breaks with the remainder containing single-stranded 
DNA breaks. The fact that a significant proportion of cleavage complexes contain single-
stranded breaks was initially taken as an indication for poor coordination between the two 
protomer subunits of topoisomerase II (72). However, in hindsight, if the protomers cut 
the two strands of the double helix in a completely non-coordinated fashion, virtually no 
double-stranded DNA breaks would be generated (1% x 1%  0.01% cleavage complexes). 
These findings suggest that there must be a relatively high degree of coordination 
between the two protomer active sites of the enzyme, even if they do not act in complete 
concert with one another. To this point, once topoisomerase II cleaves the first strand, it 
is estimated that the enzyme cuts the second strand ~20–fold faster (70). 
 Following strand passage, DNA ligation is initiated when a general acid extracts the 
hydrogen from the 3’-terminal hydroxyl group. The acid may be a water molecule or an 
unidentified amino acid in the active site of topoisomerase II. The conversion of the 
terminal hydroxyl moiety to an oxyanion induces a nucleophilic attack on the 
phosphotyrosyl bond (11,23,26,27). This action represents the reverse of the cleavage 
event and regenerates an intact DNA chain as well as the active site of topoisomerase II.  
 It should be noted that the chemical structure of the ligated DNA is identical to that 
of the original substrate. Only the topological properties of the double helix are altered by 
the actions of topoisomerase II.  
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Topoisomerase II as a Cellular Toxin 
 Proliferating cells cannot exist without type II topoisomerases (5,8,10). However, 
since these enzymes generate obligatory double-stranded DNA breaks as part of their 
reaction mechanism, they are intrinsically dangerous proteins. Thus, topoisomerase II 
assumes a Dr. Jekyll/Mr. Hyde character: while essential to cell viability, the enzyme also 
has the capacity to fragment the genome (Figure 4). Because of this dual persona, levels 
of cleavage complexes are maintained in a critical balance (5,8). When levels drop below 
threshold concentrations, daughter chromosomes remain entangled following replication. 
As a result, chromosomes cannot segregate properly during mitosis and cells die as a 
result of catastrophic mitotic failure (Figure 4). 
 When levels of cleavage complexes rise too high, cells also die, but for different 
reasons (Figure 4). Accumulated topoisomerase II-DNA cleavage intermediates are 
converted to permanent strand breaks when replication forks, transcription complexes, or 
DNA tracking enzymes such as helicases attempt to traverse the covalently bound protein 
“roadblock” in the genetic material (5,8,69,73). The resulting collision disrupts cleavage 
complexes and ultimately converts transient topoisomerase II-associated DNA breaks to 
permanent double-stranded breaks that are no longer tethered by proteinaceous bridges 
(5,8,69,73). The resulting damage and induction of recombination/repair pathways can 
trigger mutations, chromosomal translocations, and other aberrations. When these 
permanent DNA breaks are present in sufficient numbers, they can overwhelm the cell 
and initiate cell death pathways in eukaryotes (4,5,7,8,13,69,73).  
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Figure 4: Topoisomerase II is an essential but genotoxic enzyme. The formation of 
topoisomerase II-DNA cleavage complexes is required for the enzyme to perform its 
critical cellular functions. If the level of topoisomerase II-DNA cleavage complexes falls 
too low (left arrow), cells are not able to untangle daughter chromosomes and ultimately 
die of mitotic failure. If the level of cleavage complexes becomes too high (right arrow) 
the actions of DNA tracking systems can convert these transient complexes to permanent 
double-stranded breaks. The resulting DNA breaks, as well as the inhibition of essential 
DNA processes, initiate recombination/repair pathways and generate chromosome 
translocations and other DNA aberrations. If the strand breaks overwhelm the cell, they 
can trigger apoptosis. This is the basis for the actions of several widely prescribed 
anticancer drugs. If the concentration of topoisomerase-mediated DNA strand breaks is 
too low to overwhelm the cell, mutations or chromosomal aberrations may be present in 
surviving populations. In some cases, exposure to topoisomerase II poisons has been 
associated with the formation of specific types of leukemia that involve the MLL (mixed 
lineage leukemia) gene at chromosome band 11q23 or the chromosome 15;17 
translocation that joins the PML (promyelocytic leukemia) and RARA (retinoic acid 
receptor ) genes (lower right arrow) (74,75). 
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Topoisomerase II Poisons 
 Compounds that impact the catalytic activity of topoisomerase II can be separated 
into two categories. Chemicals in the first category decrease the overall activity of the 
enzyme and are known as catalytic inhibitors (5,8,69). Chemicals in the second category 
increase levels of topoisomerase II-DNA cleavage complexes. These latter compounds 
are said to “poison” the type II enzyme and convert it to a cellular toxin that initiates the 
mutagenic and lethal consequences described above (5,8,69). Because of their actions, 
these compounds are referred to as “topoisomerase II poisons” to distinguish them from 
inhibitors that do not affect enzyme mediated DNA cleavage/ligation (5,8,69). Although 
some topoisomerase II poisons also inhibit overall activity, the “gain of function” 
induced by these compounds in the cell (i.e., increased levels of cleavage complexes), is 
the dominant phenotype (8,69). 
 Topoisomerase II poisons increase the concentration of cleavage complexes by two 
non-mutually exclusive pathways. Some compounds, such as the anticancer drug 
etoposide (see below), inhibit the ability of the enzyme to ligate cleaved DNA molecules 
(5,8,69). Other poisons, such as abasic sites and other forms of DNA damage (see below) 
have little effect on ligation and are believed to work primarily by enhancing the forward 
rate of scission (8,69). Because of the manner in which they act, abasic sites poison 
topoisomerase II without inhibiting overall catalytic activity. 
 Beyond their effects on DNA scission vs. ligation, topoisomerase II poisons (with 
the exception of DNA lesions) act by two distinct mechanisms. Compounds in the first 
group are referred to as traditional, non-covalent, interfacial, or redox-independent 
topoisomerase II poisons (8,44,69,76). These chemicals form non-covalent interactions 
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with topoisomerase II at the protein-DNA interface in the vicinity of the active site 
tyrosine (8,44,76-81). Because these compounds also interact with DNA within the 
ternary enzyme-DNA-poison complex, they generally alter the DNA cleavage site 
specificity of the enzyme (82). Finally, their actions against topoisomerase II are not 
affected by reducing agents, such as dithiothreitol, and these compounds induce similar 
levels of enzyme-mediated DNA cleavage whether they are added to the binary 
topoisomerase II-DNA complex or are incubated with the enzyme prior to the addition of 
nucleic acid substrates (8,76,77,83).  
 Unlike the traditional poisons, compounds that use the second mechanism require 
redox activity to facilitate their actions against topoisomerase II. The redox-dependent 
poisons covalently adduct to the enzyme at amino acid residues outside of the active site 
(8,69,83-90) and generally enhance DNA cleavage at sites that are intrinsically cut by the 
enzyme (83,88). Moreover, because these compounds require redox chemistry for 
activation, their ability to poison topoisomerase II is abrogated by reducing agents 
(83,85,88,91-93). Finally, compounds within this group enhance DNA cleavage when 
added to the protein-DNA complex but display the distinguishing feature of inhibiting 
topoisomerase II activity when incubated with the enzyme prior to the addition of DNA 
(83,85,88,91-93). 
 
Topoisomerase II as a Target for Anticancer Drugs 
 Topoisomerase II poisons represent some of the most important and widely 
prescribed anticancer drugs currently in clinical use (Figure 5). These drugs encompass a 
diverse group of natural and synthetic compounds that are commonly used to treat a  
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Figure 5: Topoisomerase II-targeted anticancer drugs. Structures of selected drugs are 
shown. 
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variety of human malignancies (5,8,69,76,94,95). At the present time, six topoisomerase 
II-targeted anticancer agents are approved for use in the United States, and additional 
drugs are prescribed elsewhere in the world (95). These agents all act as traditional 
topoisomerase II poisons and function primarily by inhibiting enzyme-mediated DNA 
ligation. 
 One of the first topoisomerase II-targeted agents to be discovered was etoposide, 
which is derived from podophyllotoxin (94,96). This natural product is found in 
Podophyllum peltatum, more commonly known as the mayapple or mandrake plant 
(94,96). Podophyllotoxin has been used as a folk remedy for over a thousand years 
(94,96). The clinical use of this compound as an antineoplastic agent was prevented by 
high toxicity, but two synthetic analogs, etoposide and teniposide, displayed increased 
antineoplastic activity and decreased toxicity (94,96). Etoposide was approved for 
clinical use against cancer in the mid-1980’s and for several years was the most widely 
prescribed anticancer drug in the world (94,96).  
 Etoposide and other drugs such as doxorubicin (and its derivatives) are front-line 
therapy for a variety of systemic cancers and solid tumors, including leukemias, 
lymphomas, sarcomas, and breast, lung, and germline cancers (94-96). Mitoxantrone is 
used to treat breast cancer, and both it and amsacrine are used to treat relapsed acute 
myeloid leukemia (97,98). Every form of cancer that is considered to be curable by 
chemotherapy utilizes treatment regimens that include topoisomerase II-targeted drugs 
(94-96,99). In addition to the use of mitoxantrone in anticancer regimens, it is used as a 
treatment for autoimmune diseases, such as multiple sclerosis (100). 
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 Although topoisomerase II is the cytotoxic target of the drugs shown in Figure 5, the 
relative contributions of topoisomerase II and topoisomerase II to the 
chemotherapeutic effects of these agents has yet to be resolved. Some drugs appear to 
favor one isoform or the other (101); however, no truly “isoform-specific” agents have 
been identified. The issue of isoform specificity has potential clinical ramifications. For 
example, since topoisomerase II is not expressed appreciably in quiescent cells, the 
actions of topoisomerase II-targeted agents against the  isoform in differentiated tissues 
such as cardiac cells most likely are responsible for much of the off-target toxicity of 
these drugs (102-104). Alternatively, since topoisomerase II and topoisomerase II are 
involved in different cellular processes, it may be that cleavage complexes formed with 
one or the other isoform are more likely to be converted to permanent DNA strand 
breaks.  
 
Dietary Topoisomerase II Poisons 
 Many foods consumed in the human diet contain naturally occurring topoisomerase 
II poisons (Figure 6). The most prominent natural products with activity against the 
mammalian type II enzymes are the bioflavonoids (i.e., phytoestrogens) (105-108). 
Bioflavonoids represent a broad group of polyphenolic compounds (including flavones, 
flavonols, isoflavones, and catechins) that are components of many fruits, vegetables, and 
plant leaves (109-112). These compounds affect human cells through a variety of 
pathways; they are strong antioxidants and efficient inhibitors of growth factor receptor 
tyrosine kinases (109-112). In addition, many bioflavonoids, especially genistein, are 
potent topoisomerase II poisons (84,105-108,113-115).  
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Figure 6: Dietary, environmental, and DNA-based topoisomerase II poisons. 
Abbreviations used are epigallocatechin gallate (EGCG), N-acetyl-p-benzoquinone imine 
(NAPQI), and 2-(4-chloro-phenyl)-[1,4]benzoquinone (4’Cl-2,5pQ). 
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 Genistein, which is prominent in soy, is believed to be a chemopreventative agent in 
adults that contributes to the low incidence of breast and colorectal cancers in the Pacific 
Rim (Figure 6) (111,112). However, as discussed below, there also is evidence 
associating genistein consumption during pregnancy with the development of infant 
leukemias (106,116-119). In addition, (–)-epigallocatechin gallate (EGCG), the most 
abundant and biologically active polyphenol in green tea, is a topoisomerase II poison 
(Figure 6) (84,111,114). Many of the therapeutic benefits of green tea have been 
attributed to this compound. 
 The ring structure of genistein is remarkably similar to that of quinolones (115). 
These latter compounds, which target the prokaryotic type II topoisomerases DNA gyrase 
and topoisomerase IV, represent the most active and broad-spectrum antibacterials 
currently in clinical use (120-122). Like the quinolones and the anticancer drugs 
discussed above, genistein increases levels of topoisomerase II-DNA cleavage complexes 
as a traditional topoisomerase II poison (115). In contrast, since many bioflavonoids 
undergo redox chemistry, several members of the class act as redox-dependent 
topoisomerase II points. EGCG and some related catechins poison topoisomerase II by 
this latter mechanism (84,114).   
 
Environmental Topoisomerase II Poisons 
 The toxic metabolites of some drugs and industrial chemicals are topoisomerase II 
poisons (Figure 6) (86,87,89,123,124). In all cases described to date, these chemicals 
include quinones (carbon rings that feature ketone groups) as part of their structures (125-
128). Quinones commonly are produced in the body as a result of detoxification or 
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metabolism pathways (125-128). These compounds are highly reactive and often damage 
cells by generating oxidative radicals or by covalently modifying proteins and (to a lesser 
extent) nucleic acids (125-128).  
 Although acetaminophen is the most widely utilized analgesic in the world, 
overdosage (both accidental and intentional) of this drug represents the second most 
prevalent cause for toxic drug admissions to emergency departments in the United States 
(129). The toxic metabolite of acetaminophen, N-acetyl p-benzoquinone imine (NAPQI), 
is a potent topoisomerase II poison that produces liver failure (90). Benzene is an 
industrial solvent that is associated with the development of human leukemias (123,125-
128). One of the most prevalent metabolites of benzene, 1,4-benzoquinone, is a highly 
reactive topoisomerase II poison (86,87,89,123,124). Finally, polychlorinated biphenyls 
(PCBs), which have multiple industrial uses, have been linked to a variety of human 
health issues (88). The quinone metabolites of these compounds all display activity 
against human type II topoisomerases. Consistent with their highly active redox 
chemistry, all quinone-based topoisomerase II poisons act in a redox-dependent manner 
that involves covalent attachment to the enzyme (85-87,91). 
 
DNA Damage as Topoisomerase II Poisons 
 Several forms of nucleic acid damage enhance topoisomerase II-mediated DNA 
cleavage (Figure 6) (64,130-137). The type II enzymes are particularly sensitive to abasic 
sites, alkylated bases that contain exocyclic rings, and other lesions that distort the double 
helix. 
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 DNA damage increases cleavage at naturally occurring sites of topoisomerase II 
action (64,130-137). To enhance cleavage, lesions must be located within the four-base 
stagger that separates the two scissile bonds (64,130-137).  
 The physiological benefits of DNA lesions as topoisomerase II poisons, if any, are 
unclear. However, human topoisomerase II and topoisomerase II both appear to play 
roles in fragmenting genomic DNA and releasing chromosomal loops during apoptosis 
(138,139). It has been suggested that the apoptotic activities of topoisomerase II are 
enhanced (or perhaps triggered) by DNA lesions that are generated following the release 
of oxidative radicals from permeable mitochondria in apoptotic cells (138,139). 
 
Topoisomerase II and Leukemia 
 Despite the importance of topoisomerase II in cancer chemotherapy, evidence 
suggests that DNA cleavage mediated by the enzyme can trigger chromosomal 
translocations that lead to specific types of leukemia (see Figure 4) (5-8,69,140,141). To 
this point, 2-3% of patients who receive regimens that include etoposide or other 
topoisomerase II-targeted drugs eventually develop acute myeloid leukemias (AMLs). 
Most of these leukemias are accompanied by translocations with breakpoints in the MLL 
(mixed lineage leukemia) gene at chromosomal band 11q23 (6,7,69). The MLL protein is 
a histone methyltransferase that regulates the Hox genes, which control proliferation in 
hematopoietic cells (6,7,69). Several breakpoints in MLL have been identified and are 
located in close proximity to topoisomerase II-DNA cleavage sites (6,7,69).  
 Recently, a link between topoisomerase II-targeted drugs and the development of 
acute promyelocytic leukemias (APLs) has been observed. Patients with these leukemias 
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display translocations between the PML (promyelocytic leukemia) gene on chromosome 
15 and the RARA (retinoic acid receptor ) gene on chromosome 17 (74,75). 
 In addition to treatment-related leukemias, ~80% of infants with AML or acute 
lymphoblastic leukemia (ALL) display translocations that involve the MLL gene 
(6,7,106,116-118,140-142). The chromosomal translocations associated with these 
cancers have been observed in utero, indicating that infant leukemias are initiated during 
pregnancy. Epidemiological studies indicate that the risk of developing these infant 
leukemias is increased >3-fold by the maternal consumption of foods that are high in 
naturally occurring topoisomerase II poisons such as genistein or other bioflavonoids 
(106,116-119).  
 The ability of topoisomerase II poisons to cause rather than cure cancer may be 
related to cellular levels of topoisomerase II-mediated DNA cleavage complexes. If the 
concentration of enzyme-associated DNA breaks is sufficient, DNA recombination/repair 
pathways can be overwhelmed and cells will die (5,8,69). However, if the levels of 
breaks are not adequate to induce death, pathways that promote cell survival can lead to 
the formation of stable chromosomal translocations that ultimately lead to cancerous 
growth (Figure 4) (5,8,69).  
 Finally, the specific contributions of topoisomerase II and topoisomerase II to 
cancer therapy vs. leukemogenesis are unclear. However, recent evidence suggests that 
(with at least some drugs) topoisomerase II may play a more important role in 
cytotoxicity (102,143), while topoisomerase II may play a greater role in triggering 
drug-induced cancers (102).  
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Scope of the Dissertation 
The DNA cleavage reaction of topoisomerase II is essential to the function of the 
enzyme and is required for the effects of topoisomerase II-targeted poisons. Therefore, it 
is necessary to have a clear understanding of the process of DNA cleavage by the 
enzyme. The goals of this dissertation are to establish a DNA cleavage system that 
separates enzyme-mediated cleavage from ligation, examine the coordination of the two 
protomers during cleavage, and determine the role of required metal ions during scission.  
 An overview of DNA topology and topoisomerases is found in Chapter I. The 
materials and methods used in this dissertation are located in Chapter II. 
 Chapter III of this dissertation describes the development of a system for examining 
topoisomerase II-mediated DNA cleavage in the absence of ligation using 3’-bridging 
phosphorothiolates. Findings made using this system have been published (144) and 
demonstrate that 3’-bridging phosphorothiolate substrates are cleaved by topoisomerase 
II in a covalent and metal-ion dependent manner. Further, enzyme-mediated cleavage of 
these substrates accumulates over time and cannot be reversed even in the presence of 
high salt or EDTA.  
 Chapter IV of this dissertation describes the coordination of the two protomer 
subunits of topoisomerase II and the ability of nicks to poison the type II enzyme. This 
work has been accepted for publication (145) and demonstrates that second-strand DNA 
cleavage occurs faster than first-strand DNA cleavage, allowing the enzyme to be 
suitably coordinated during scission. Based on the results, we believe that once the 
enzyme cuts the first strand, the DNA is more flexible and attains the transition state 
more readily in order for second strand cleavage to occur. These findings also show that 
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nicks poison topoisomerase II by enhancing the forward rate of DNA cleavage without 
inhibiting DNA ligation.  
 Chapter V of this dissertation describes the role of metal ions in the DNA scission 
reaction of human topoisomerase II. Results demonstrate that there is a critical 
interaction between a metal ion and the 3’-bridging atom of DNA that may stabilize a 
transition state during scission. This work has been published (146) and indicates that two 
metal ions are involved in DNA cleavage mediated by topoisomerase II. Moreover, 
point mutations of several conserved Asp residues (D541, D543, and D545) and a Glu 
residue (E461) in topoisomerase II were generated and characterized. Results suggest 
that these residues are required for DNA cleavage and are involved in coordination of 
metal ions during scission. 
 Chapter VI of this dissertation describes the involvement of metal ions during 
scission by human topoisomerase II. Results demonstrate that the  isoform also uses a 
two metal ion mechanism similar to that of topoisomerase II. This work has been 
accepted for publication (147) and provides evidence that the mechanism of type II 
topoisomerases involve an interaction between a metal ion and a non-bridging phosphate 
oxygen. Although a non-bridging interaction is frequently postulated in models for metal 
ion usage by topoisomerases, this evidence from topoisomerase II is the first 
biochemical demonstration that a metal ion does contact this position during scission.  
Concluding remarks for the research presented in this dissertation are provided in 
Chapter VII. 
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CHAPTER II 
 
METHODS 
 
Materials 
 
Enzymes  
 Human topoisomerase II and II were expressed in Saccharomyces cerevisiae and 
purified as described previously (130,148,149). Yeast (S. cerevisiae) topoisomerase II 
was isolated as described previously (77,149). 
 Individual point mutations in human topoisomerase II were made using the 
PCR-based Lightning Mutagenesis Kit (Strategene).  D541, D543, D545, and E461 were 
individually mutated to either Cys or Ala in the inducible overexpression YEpWOB6 
plasmid. Primer sequences were as follows: D545C forward 5’ – GGAAGATAATG 
ATTATGACAGATCAGGACCAATGTGGTTCCCACATC – 3’; reverse  5' – GATGT 
GGGAACCACATTGGTCCTGATCTGTCATAATCATTATCTTCC – 3'; D545A 
forward 5’ – GGAAGATAATGATTATGACAGATCAGGACCAAGCTGGTTCCCAC 
ATC – 3’; reverse 5' – GATGTGGGAACCAGCTTGGTCCTGATCTGTCATAATCAT 
TATCTTCC – 3'; D543C forward 5’ – GGAAGATAATGATTATGACA GATCAGTG 
CCAAGATGGTTCCCACATC – 3’; reverse 5' – GATGTGGGAACCATCTTGGC 
ACTGATCTGTCATAATCATTATCTTCC – 3'; D543A forward 5’ – GGAAGATAA 
GATTATGACAGATCAGGCCCAAGATGGTTCCCACATC – 3’; reverse 5' – GATGT 
GGGAACCATCTTGGGCCTGATCTGTCATAATCATTATCTTCC – 3'; D541C 
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forward 5’ – GGAAGATAATGATTATGACATGTCAGGACCAAGATGGTTCCCA 
CATC – 3’; reverse 5' – GATGTGGGAACCATCTTGGTCCTGACATGTCATAATC 
ATTATCTTCC – 3'; D541A forward 5’ – GGAAGATAATGATTATGACAGCTCA 
GGACCAAGATGGTTCCCACATC – 3’; reverse 5' – GATGTGGGAACCATCTTGGT 
CCTGAGCTGTCATAATCATTATCTTCC – 3'; E461C forward 5’ – GAGTGTACGCT 
TATCCTGACTTGTGGAGATTCAGCCAAAACTTTGGCTG – 3’; reverse 5’ – CAG 
CCAAAGTTTTGGCTGAATCTCCACAAGTCAGGATAAGCGTACACTC – 3’; and 
E461A forward 5’ – GAGTGTACGCTTATCCTGACTGCGGGAGATTCAGCCAAAA 
CTTTGGCTG – 3’; reverse 5’ – CAGCCAAAGTTTTGGCTGAATCTCCCGCAGTC 
AGGATAAGCGTACACTC – 3’. Mutants were isolated, sequenced, and transformed 
back into JEL1top1 yeast cells where they were expressed and purified as mentioned 
above (130,148,149).  
 
 
 Preparation of Oligonucleotides  
 Two 50-bp oligonucleotide duplexes were designed using previously identified 
topoisomerase II cleavage sites from pBR322. These sites correspond to sequences 
designated as site 1 and site 2 by Fortune et al. (150). Wild-type oligonucleotide 
sequences were generated using an Applied Biosystems DNA synthesizer. The 50-mer 
site 1 sequence for the top and bottom strands were 5’–
AGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAG-
3’ and 5’–CTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGAT-
ACCGCT-3’, respectively (arrow denotes point of cleavage). The 50-mer site 2 top and 
bottom sequences were 5’-TTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT-
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CGGAAAAAGAGTTGGT-3’ and 5’-ACCAACTCTTTTTCCGAAGGTAACTGGCT-
TCAGCAGAGCGCAGATACCAA-3’, respectively. Nested 40-, 30-, 25-, and 20-mer 
oligonucleotides were generated by incrementally shortening the 50-mer site 2 sequence 
from each end and maintaining the central cleavage site. The sequences used for the 
bottom strand of these shortened oligonucleotides were 5’–AACTCTTTTTCCGAAGG-
TAACTGGCTTCAGCAGAGCGCAG-3’, 5’–TTTTTCC-GAAGGTAACTGGCTT-
CAGCAGAG-3’, 5’-TTTTTCCGAAGGTAACTGGCTTC-AG-3’, and 5’-TTCCGA-
AGGTAACTGGCTTC-3’, respectively. Depending on the experiment, the top strand 
was either the complementary sequence of the same length or the full-length 50-mer site 
2 top strand sequence.  
 The top and bottom sequences for the 50-mer substrate that did not contain a native 
cleavage site were 5’-ACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAA 
CAAACCACCGC-3’ and 5’-GCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAAC 
TCTTTTTCCGAAGGT-3’, respectively. The “non-cleavage” sequence that was selected 
is located proximal to the site 2 sequence shown above. In the absence of anticancer 
drugs or other poisons, no cleavage by human topoisomerase II was observed anywhere 
within the oligonucleotide. A few sites of enzyme-mediated scission in the “non-
cleavage” substrate were seen in the presence of 100 M amsacrine or etoposide (data 
not shown). However, neither drug generated cleavage complexes at the positions 
induced by nick 1, 2, or 3, with the following exception: etoposide produced ~0.13% 
cleavage at the position induced by nick 3. This level of scission is ~1/3 that generated by 
the presence of nick 3. 
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 Oligonucleotide duplexes with site-specific nicks were generated by annealing the 
full length (50-mer) bottom strand with two complementary fragments generated from 
the top strand sequence. The lengths of the two fragments were altered to move the 
position of the nick on the top strand. In some cases, oligonucleotides contained a 
tetrahydrofuran abasic site analog in place of a specific nucleotide. The positions of these 
alterations (i.e., nicks or abasic sites) are denoted in the appropriate experiments. 
Substrates containing a racemic phosphorothioate in place of the non-bridging scissile 
bond oxygens of the bottom strand of site 1 and site 2 were synthesized by Operon. 
 
Preparation of Phosphorothiolate Oligonucleotides  
 DNA containing a single 3'-bridging phosphorothiolate linkage at the site of 
topoisomerase II-mediated cleavage was synthesized using 3'-S-(2-cyanoethyl-N,N-
diisopropylphosphorothioamidite)-3'-deoxy-5'-O-(4,4'-dimethoxytrityl)thymidine (151).  
The synthesis of the DNA oligonucleotide was performed on an ABI392 DNA 
synthesizer (Applied Biosystems) similar to published protocols (152) except that 
standard activator (0.45 M tetrazole in CH3CN) and low iodine containing oxidizing 
solution (0.02 M I2 in tetrahydrofuran/pyridine/water) were used during all coupling and 
oxidation steps. All reagents for DNA synthesis were purchased from Glen Research. 
DNA oligonucleotides were deprotected in concentrated ammonia (Aldrich) containing 
0.1% -mercaptoethanol (Aldrich) at room temperature for 48 h, and partially purified by 
reverse phase HPLC chromatography as described previously (153). Unless stated 
otherwise, the location of the phosphorothiolate was always on the bottom strand at the 
scissile bond (denoted by the arrow). Confirmation of the presence of the bridging sulfur 
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was accomplished by treating oligonucleotides with AgNO3 (154) and resolving 
fragments by gel electrophoresis. 
 
Radioactive Labeling of Oligonucleotides 
 [-32P]ATP (~5000 Ci/mmol) was obtained from ICN. Single-stranded 
oligonucleotides were labeled on their 5’ termini using T4 polynucleotide kinase (New 
England Biolabs). Labeling of 3’ termini with [-32P]cordycepin (ICN) was performed 
using terminal deoxynucleotidyl transferase (New England Biolabs). Following labeling 
and gel purification, complementary oligonucleotides were annealed by incubation at 70 
°C for 10 min and cooling to 25 °C.  
 
 
DNA Cleavage Mediated by Topoisomerase II 
 
Oligonucleotide DNA Cleavage Assays 
 DNA cleavage assays were carried out by a modification of the procedure of Fortune 
et al. (150). Unless indicated, oligonucleotide substrates were 5’-end-labeled. DNA 
cleavage reactions with human type II topoisomerases contained 200 nM human 
topoisomerase II or II and 100 nM double-stranded oligonucleotide in a total of 20 μL 
of cleavage buffer: 10 mM Tris-HCl (pH 7.9), 135 mM KCl, 5 mM divalent cation 
(MgCl2, unless otherwise stated), 0.1 mM EDTA, and 2.5% glycerol (v/v). Reactions 
with yeast topoisomerase II contained 200 nM enzyme and 100 nM double-stranded 
oligonucleotide in a total of 20 μL of 10 mM Tris-HCl (pH 7.9), 35 mM KCl, 100 mM 
NaCl, 5 mM MgCl2, 0.1 mM Na2EDTA, and 2.5% glycerol (v/v). Reactions were 
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initiated by the addition of enzyme and were incubated at 37 °C (human) or 28 °C (yeast) 
for 0 to 30 min. DNA cleavage products were trapped by the addition of 2 μL of 10% 
SDS followed by 2 μL of 250 mM Na2EDTA (pH 8.0). Proteinase K (2 μl of 0.8 mg/mL) 
was added to digest the enzyme, and cleavage products were resolved by electrophoresis 
in a 14% denaturing polyacrylamide gel. DNA cleavage products were visualized and 
quantified using a Bio-Rad Molecular Imager. 
 As a test of the reversibility of topoisomerase II-mediated cleavage, 2 μL of 250 mM 
Na2EDTA (pH 8.0) or 2 L of 5 M NaCl were added and samples were incubated at 37 
°C for 5 min prior to the addition of SDS. Reactions with ATP contained a final 
concentration of 1 mM. In some cases, assay mixtures included 50 μM etoposide or 
amsacrine. In some cases, the concentration of divalent cation (MgCl2, MnCl2, CaCl2, or 
CoCl2) was varied and/or combinations of cations were used. Studies incorporating 
experiments that monitored DNA cleavage over a range that included divalent cation 
concentrations below 1 mM utilized cleavage buffer that lacked EDTA. To inhibit 
oxidation of cleaved oligonucleotides containing 3’-terminal –SH moieties and the 
formation of multimers in the gel, 100 mM DTT was added to the sample loading buffer.  
 
Pre-equilibrium Oligonucleotide DNA Cleavage 
 In order to determine rate constants for DNA cleavage, pre-equilibrium reactions 
were monitored for 5 ms to 3 s using a KinTek (Austin, TX) model RQF-3 chemical 
quench flow apparatus. Cleavage was initiated by rapidly mixing nearly equal volumes of 
two independent solutions. The first contained a noncovalent complex formed between 
human topoisomerase II and 32P-labeled oligonucleotide in cleavage buffer that lacked 
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divalent cation. The second solution contained cleavage buffer in which the divalent 
cation concentration was 2 times higher than normal (10 mM). The two solutions were 
mixed at 37 ºC, and DNA cleavage was quenched with 1% SDS (v/v final concentration). 
Products were processed and analyzed as described above. The observed rate constant of 
DNA cleavage was determined by a fit of the data to the double exponential equation y = 
b1(1 – e
-k1t) + b2(1 – e
-k2t), where y is the percent of DNA cleavage, b is the amplitude, k is 
the observed rate constant, and t is the time. 
 Since assays were initiated by the addition of a divalent metal ion to a pre-formed 
topoisomerase II-DNA complex, in the simplest case, cleavage should follow first order 
reaction kinetics. However, time courses for pre-equilibrium DNA cleavage reactions 
were best fitted to a double exponential equation. Two previous studies that examined 
pre-equilibrium DNA cleavage by topoisomerase II, one with the yeast type II enzyme 
(70) and the other with human topoisomerase II (see chapter V), also found that the best 
fit for the reaction was to a double exponential equation. 
 The mechanistic basis underlying this fit is not obvious. However, the most likely 
possibility is that there is a conformational change in the enzyme-DNA complex that 
occurs between the DNA binding and cleavage steps. This change may represent either a 
requisite conversion from a non-productive to a productive state or an isomerization from 
a less active to a more active state. Such a proposed conformational change is suggested 
by kinetic analysis of the DNA binding, cleavage, and ligation events mediated by yeast 
topoisomerase II (70). In addition, it is supported by the fact that the orientation of the 
active site tyrosyl residue in the crystal structure of the non-covalent complex between 
DNA and the catalytic core of yeast topoisomerase II is too far away from the scissile 
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bond to initiate scission (65). This finding implies that the enzyme active site in the 
structure “has not yet attained a cleavage competent configuration.” 
 
Topoisomerase II-mediated Plasmid DNA Cleavage  
 Plasmid DNA cleavage reactions were performed using the procedure of Fortune 
and Osheroff (155). Reaction mixtures contained 200 nM human topoisomerase II and 5 
nM negatively supercoiled pBR322 DNA in 20 μL of DNA cleavage buffer as defined 
above with 5 mM MgCl2. DNA cleavage mixtures were incubated for 10 min at 37 °C. 
EnzymeDNA cleavage complexes were trapped by adding 2 μL of 5% SDS followed by 
2 μL of 250 mM Na2EDTA (pH 8.0). Proteinase K was added (2 μL of a 0.8 mg/mL 
solution), and reaction mixtures were incubated for 30 min at 37 °C to digest 
topoisomerase II. Samples were mixed with 2 μL of 60% sucrose in 10 mM Tris-HCl (pH 
7.9), 0.5% bromophenol blue (w/v), and 0.5% xylene cyanol FF (w/v), heated for 2 min 
at 45 °C, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate (pH 
8.3) and 2 mM EDTA containing 0.5 μg/mL ethidium bromide. Single-stranded and 
double-stranded DNA cleavage was monitored by the conversion of negatively 
supercoiled plasmid DNA to nicked and linear molecules, respectively. DNA bands were 
visualized by ultraviolet light and quantified using an Alpha Innotech digital imaging 
system. 
 
Oligonucleotide DNA Ligation Assays 
 DNA ligation assays were carried out by a modification of the procedure of Kingma 
et al. (156). DNA cleavage/ligation equilibria were established as described for human 
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topoisomerase II in the oligonucleotide DNA cleavage section except that 5 mM CaCl2 
replaced the MgCl2 in the cleavage buffer. Topoisomerase II-DNA cleavage complexes 
were trapped by the addition of Na2EDTA (pH 8.0) to a final concentration of 6 mM, 
followed by NaCl to a final concentration of 0.5 M to prevent re-cleavage of the DNA. 
Ligation was initiated by the addition of MgCl2 to a final concentration of 0.1 mM and 
terminated by the addition of 2 μL of 10% SDS. Samples were processed and analyzed, 
and levels of cleavage were quantified as described above. The percent DNA cleavage at 
time zero was set to 100%, and the rate of ligation was determined by quantifying the 
loss of cleaved DNA over time. 
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CHAPTER III 
 
USING 3’-BRIDGING PHOSPHOROTHIOLATES TO ISOLATE THE FORWARD 
DNA CLEAVAGE REACTION OF HUMAN TOPOISOMERASE II 
 
 
Introduction 
 To fully understand the basis for topoisomerase II action and the role of the type II 
enzyme in curing and causing cancer, it is essential to characterize the mechanism by 
which they cleave and ligate DNA. Unfortunately, these reactions have been difficult to 
study for two major reasons. First, the DNA cleavage/ligation equilibrium of mammalian 
type II topoisomerases lies heavily toward ligation (5,8,44,60-62,71). Consequently, in 
unperturbed systems, levels of cleavage complexes generated by type II enzymes, 
including human topoisomerase II, are extremely low (<1%). To overcome this 
challenge, it is common to include topoisomerase II poisons, such as anticancer drugs 
(5,8,44) or DNA substrates that contain damaged or missing bases, in reaction mixtures 
(33,133,136,156). The use of non-physiological divalent cations such as Ca(II) or Co(II) 
also has been reported (157,158). Although all of these conditions shift the 
cleavage/ligation equilibrium of topoisomerase II toward the cleaved state, they often 
perturb the specificity of the enzyme. Furthermore, since they do not uncouple the two 
reaction steps from one another (see below), in most cases they cannot be used to reveal 
intrinsic properties of the DNA cleavage or ligation reactions. 
 Second, the DNA cleavage and ligation reactions of type II topoisomerases are 
tightly coupled (5,8,44,61,62,150,157). Because these reactions take place in a highly 
concerted fashion, it often is difficult to specifically ascribe a given effect to either 
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catalytic event. Several approaches have been employed to separate the DNA cleavage 
and ligation reactions and study them independently. “Suicide substrates” represent the 
primary approach that has been used in an attempt to isolate the forward DNA cleavage 
reaction of topoisomerase II (159-164). These DNA substrates all contain perturbations 
or non-B-form structures, such as nicks, double strand/single strand junctions, or 
hairpins. With “normal” intact B-form substrates, both halves of the cleaved DNA 
intermediate are covalently attached to topoisomerase II. In contrast, when suicide 
substrates are cut by the enzyme, one of the DNA halves is held in place by non-covalent, 
rather than covalent, interactions. If the “non-covalent” portion of the cleaved DNA 
dissociates from topoisomerase II, the enzyme is unable to rejoin the original substrate. 
This process results in a time-dependent accumulation of cleavage complexes (159-164). 
Although results with suicide substrates often are interpreted as representative of a 
unidirectional forward cleavage reaction, evidence suggests that topoisomerase II actually 
establishes a short-lived cleavage/ligation equilibrium with these substrates prior to the 
dissociation event (162). As a result, some conditions that impair the ability of 
topoisomerase II to reseal DNA breaks could increase the rate of accumulation of 
“trapped” cleavage complexes, even though they have no direct effect on the DNA 
scission reaction. This could lead to erroneous mechanistic conclusions regarding the 
actions of anticancer drugs or other topoisomerase II poisons. 
 In contrast to DNA cleavage, a number of approaches have been utilized to isolate 
the ligation reaction of topoisomerase II (33,60,165-169). These include ligation of 
cleavage complexes generated with suicide substrates to acceptor oligonucleotides, 
manipulation of the divalent cation, shifting reactions to suboptimal temperatures, or the 
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use of oligonucleotide substrates with activated 5’-terminal phosphates. The last 
approach has the advantage that it does not require the enzyme to cleave the substrate 
prior to ligation (168,169). 
  The goal of the work described in this chapter was to uncouple the DNA cleavage 
reaction of topoisomerase II from ligation. To this end, a novel system was developed 
that employed oligonucleotide substrates containing a 3’-bridging phosphorothiolate at 
the scissile bond. Similar DNA substrates containing 5’-bridging phosphorothiolates have 
been used to provide important mechanistic information about human, bovine, and pox 
virus type IB topoisomerases as well as bacteriophage lambda integrase (153,170-173). 
[5’-Bridging phosphorothiolates were used in these studies because type IB 
topoisomerases and lambda integrase form covalent links to the 3’-terminal phosphates of 
cleaved DNA (11,22,24,174), as opposed to the 5’-linkage formed with eukaryotic 
topoisomerase II (5,8,22,26,27,44,61,62).] 5’-Bridging phosphorothiolate 
oligonucleotides ligate extremely poorly (rates of ligation mediated by bovine 
topoisomerase I were <1% those observed for corresponding wild-type oligonucleotides) 
(171), and have been used in structural studies to trap the cleavage complex formed with 
human topoisomerase I (175-180). 
 The use of 3’-bridging phosphorothiolate oligonucleotides to study topoisomerase II 
mechanism has significant advantages over previous systems. In contrast to suicide 
substrates, phosphorothiolate-containing oligonucleotides are fully double-stranded B-
form DNA and display no evidence of being ligated by topoisomerase II. Results with 
human topoisomerase II indicate that phosphorothiolate-containing oligonucleotides can 
be utilized effectively to examine the DNA cleavage reaction of the enzyme in isolation 
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and provide information regarding the mechanism of action of type II topoisomerases and 
topoisomerase II poisons. 
Results and Discussion 
 
3’-Bridging Phosphorothiolates  
 The forward DNA cleavage reaction of type II topoisomerases has been difficult to 
study because it exists in a tightly coupled equilibrium with the reverse ligation reaction 
(5,8,44,61,62,150,157). Furthermore, equilibrium levels of cleavage are low (5,8,44,60-
62,71). Therefore, in order to establish a system that isolates topoisomerase II-mediated 
DNA scission from ligation and allows the unidirectional accumulation of cleavage 
complexes, double-stranded oligonucleotide substrates that contained a 3’-bridging 
phosphorothiolate at the scissile bond were synthesized (Figure 7).  
 In contrast to cleavage of wild-type DNA, which generates a 3’-terminal –OH 
moiety, cleavage of substrates that contain a 3’-bridging phosphorothiolate generates a 
3’-terminal –SH group. While the terminal –OH group is a good nucleophile that readily 
facilitates ligation, the terminal –SH group is very poor nucleophile that does not 
efficiently attack the phosphotyrosyl protein-DNA bond (153) (171). Consequently, once 
phosphorothiolate substrates are cleaved, they should not be able to support appreciable 
levels of topoisomerase II-mediated DNA ligation.  
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Figure 7: Schematic of topoisomerase II-mediated cleavage of DNA containing a 3’-
bridging phosphorothiolate. As diagrammed in the top of the figure, the oxygen at the 3’-
bridging position of the scissile bond is replaced with sulfur. Cleavage of this substrate 
generates a 5’-terminal phosphate that is covalently attached to the enzyme and a 3’-
terminal –SH moiety (instead of the –OH group seen with wild-type DNA). In contrast to 
–OH, the –SH moiety is a poor nucleophile in this context and cannot readily support 
ligation. The sequence of the central portions of site 1 and site 2 are shown at the bottom. 
The phosphorothiolate modification (denoted “S”) is on the bottom strand of these 
sequences at the scissile bond (–1/+1 position). Scissile bonds are denoted by arrows. 
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Cleavage of Oligonucleotide Substrates Containing 3’-Bridging Phosphorothiolates by 
Human Topoisomerase II  
 
 The ability of human topoisomerase II to cleave a 5’ end-labeled oligonucleotide 
substrate (denoted site 2 in Figure 7) containing a 3’-bridging phosphorothiolate at the 
scissile bond is shown in Figure 8. Scission took place at the predicted scissile bond (lane  
5), generating the expected 21-mer product (lane 2). Characteristic of a topoisomerase II-
mediated DNA reaction, cleavage required both the human enzyme and a divalent cation 
(compare lane 5 to lanes 3 and 4). Following a 30-min incubation, cleavage of the 
phosphorothiolate-containing substrate was dramatically higher than observed with the 
wild-type phosphate-containing oligonucleotide (compare lanes 5 and 6). Similar results 
were seen for the site 1 phosphorothiolate oligonucleotide (not shown). Finally, when the 
site 2 phosphorothiolate oligonucleotide was incubated with AgNO3, which hydrolyzes 
S-P bonds (154), a 21-mer product resulted (lane 8). This last control demonstrates both 
the presence of the 3’-bridging phosphorothiolate and its location at the scissile bond.  
 Although cleavage at the 3’-bridging phosphorothiolate requires topoisomerase II 
and Mg(II), it is possible that the environment of the enzyme active site promotes a 
cleavage event that is independent of the active site tyrosyl residues. A hallmark of 
topoisomerase II-mediated scission is a covalent linkage between the cleaved DNA and 
the protein. Therefore, the 3’-bridging phosphorothiolate site 2 substrate was labeled on 
its 3’-terminus to determine whether the product was covalently linked to topoisomerase 
II (Figure 9). Once again, cleavage was observed only in the presence of enzyme. 
Following treatment with proteinase K, cleavage products were seen as a diffuse series of 
bands that ran with a mobility that was faster than that of the substrate band (lane 3). 
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Figure 8: Topoisomerase II-mediated cleavage of the site 2 oligonucleotide containing a 
3’-bridging phosphorothiolate at the scissile bond. An autoradiogram of a polyacrylamide 
gel is shown. The substrate is denoted at the top (Oligo): S, 3’-bridging phosphorothiolate 
substrate; O, wild-type substrate; 21, 21-mer marker. The presence of enzyme (TII) or 
divalent cation (Mg
2+
) is denoted by a plus (+) and the absence by a minus (–). The 
migration of the 50-mer substrate and the 21-mer cleavage product are denoted on the left 
side. It is notable that the presence of the 3’-terminal –SH moiety slightly retards the 
electrophoretic mobility of phosphorothiolate cleavage products as compared to wild-
type standards with 3’-terminal –OH groups. The addition of AgNO3 to cleave the S-P 
bond is denoted by Ag in lane 8. For this and all subsequent figures, the concentrations of 
topoisomerase II and oligonucleotide substrate were 200 nM and 100 nM, respectively. 
Data are representative of four independent experiments. 
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Figure 9: Covalent protein-DNA linkage occurs when the site 2 oligonucleotide 
containing a 3’-bridging phosphorothiolate is cleaved by topoisomerase II. An 
autoradiogram of a polyacrylamide gel is shown. Substrates were 3’ end-labeled and 
reacted with topoisomerase II. Lanes 1 and 2 were in the absence of enzyme (–TII) 
with (+) or without (–) proteinase K (Pro K). Lane 3 and 4, were in the presence of 
enzyme (+TII) with or without proteinase K. Data are representative of three 
independent experiments. 
Origin 
Substrate 
Pro K   +   -   +   - 
Cleavage 
Product 
-TII  +TII 
           1   2   3   4 
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These product bands are indicative of cleaved oligonucleotides that are linked to small 
peptides that are not completely digested by proteinase K. To confirm the protein-DNA 
linkage, proteinase K was omitted from the reaction (lane 4). The cleavage product bands 
disappeared and were replaced by a DNA band that remained at the origin. These results 
demonstrate that cleavage products generated with a 3’-bridging phosphorothiolate at the  
scissile bond are covalently attached to topoisomerase II. Together with the data shown 
in Figure 8, these findings provide strong evidence that topoisomerase II cleaves the 
phosphorothiolate oligonucleotide in a manner that is consistent with the normal scission 
reaction of the enzyme. 
 Time courses for the cleavage of site 1 and site 2 by human topoisomerase II are 
shown in Figure 10. Comparable results were observed with both sequences. Two 
striking features were seen. First, levels of cleavage of the phosphorothiolate substrate 
were dramatically higher (~10– to 100–fold at 30 min) than were generated with the 
comparable wild-type oligonucleotides. Second, while a cleavage/ligation equilibrium 
was reached rapidly with both wild-type substrates, levels of cleaved phosphorothiolate 
oligonucleotides continued to accumulate until 20–30 min. Both of these features are 
characteristic of reactions in which the ability of topoisomerase II to ligate cleaved 
DNA molecules is either blocked or severely compromised. Similar results were seen 
when the site 2 phosphorothiolate substrate was cleaved by yeast topoisomerase II or 
human topoisomerase II (Figure 11). Albeit, levels of cleaved products were somewhat 
lower with these latter two enzymes. Taken together, these findings indicate that 3’-
bridging phosphorothiolates can be used with a variety of type II topoisomerases and 
DNA cleavage sites. 
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Figure 10: Time-courses for cleavage of oligonucleotide substrates by topoisomerase II. 
Results for site 1 (left panel) and site 2 (right panel) are shown. The asterisk (*) denotes 
the 5’ end-labeled strand (top, T; or bottom, B) on which cleavage was monitored. The 
wild-type duplex containing an O-P scissile bond (subscript O) is denoted by T/BO* for 
the labeled bottom strand (open circles) and T*/BO for the labeled top strand (open 
squares). The phosphorothiolate substrate containing an S-P scissile bond (subscript S) is 
denoted by T/BS* for the labeled phosphorothiolate bottom strand (closed circles) and 
T*/BS for the labeled wild-type top strand (closed squares). Error bars represent the 
standard deviation of at least three independent experiments. 
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Figure 11: Ability of eukaryotic type II topoisomerases to cleave the phosphorothiolate 
substrate. Time courses are shown for cleavage of the bottom strand of a site 2 
oligonucleotide containing a phosphorothiolate S-P linkage at the scissile bond of the 
bottom strand by human topoisomerase II (hTopoII, closed circles), human 
topoisomerase II (hTopoII, closed squares), and yeast topoisomerase II (yTopoII, open 
circles). Error bars represent the standard deviation of at least three independent 
experiments. 
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Cleavage of 3’-Bridging Phosphorothiolate Substrates is Sequence Specific  
 Type II topoisomerases cleave DNA with an intrinsic specificity (63). The above 
experiments demonstrate that human topoisomerase II cleaves an S-P linkage when it is 
situated at the scissile bond of an established topoisomerase II-DNA recognition 
sequence. However, it is not known whether the ability of the enzyme to cut the S-P 
linkage requires the bond to be situated at a “normal” cleavage site or is independent of 
the intrinsic sequence specificity of the protein. 
 To address this critical issue, the phosphorothiolate of site 1 was moved one position 
from the natural scissile bond, bridging the -1/+1 nucleotides, to a location bridging the 
+1/+2 nucleotides (Figure 12). In contrast to the high levels of scission generated when 
the S-P linkage was situated at the normal -1/+1 position (compare lanes 1 and 2), 
virtually no cleavage was seen at the S-P bond when it was moved to the +1/+2 position 
(compare lanes 4 and 6). As a control, to ensure that the oligonucleotide with the +1/+2 
S-P bond was capable of being recognized and cleaved by topoisomerase II, scission at 
the -1/+1 position was monitored. While cleavage at the normal scissile bond was 
decreased somewhat compared to that seen with the completely wild-type oligonucleotide 
(compare lanes 1 and 3), a significant level of scission still was observed. Taken together, 
these data demonstrate that the specificity of topoisomerase II is not altered by the 
presence of the 3’-bridging phosphorothiolate.  
 
Cleavage of 3’-Bridging Phosphorothiolates by Topoisomerase II Is Not Reversible  
 Topoisomerase II-mediated cleavage of oligonucleotides that contain a 3’-bridging 
phosphorothiolate at the scissile bond generate products with a 3’-terminal –SH group  
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Figure 12: Site-specificity of DNA cleavage mediated by topoisomerase II is not altered 
by the location of the 3’-bridging phosphorothiolate. Cleavage was monitored on three 
versions of the site 1 substrate: wild-type duplex containing an O-P linkage at both the –
1/+1 and +1/+2 positions; duplex containing an S-P linkage at the normal scissile bond (–
1/+1 position) and an O-P linkage at the +1/+2 position; and duplex containing an O-P 
linkage at the normal scissile bond (–1/+1 position) and an S-P linkage at the +1/+2 
position. Cleavage was quantified at the   –1/+1 position (lanes 1-3, 22-mer product) and 
the +1/+2 position (lanes 4-6, 23-mer product). The nature of the linkage at the bridging 
position (O-P linkage, O; S-P linkage, S: bolded when being monitored) is denoted at the 
top of the figure. A representative gel is shown in the inset. The positions of the intact 50-
mer substrate (Sub) as well as 22-mer and 23-mer standards (Std) representing cleavage 
products at the -1/+1 and +1/+2 sites, respectively, are indicated. As noted in Figure 2, 
the presence of the 3’-terminal –SH moiety slightly retards the electrophoretic mobility of 
phosphorothiolate cleavage products as compared to wild-type standards with 3’-terminal 
–OH groups. Error bars represent the standard deviation of three independent 
experiments. 
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(see Figure 7). Previous studies with type I topoisomerases and 5’-bridging 
phosphorothiolate substrates suggest that the –SH group should not be able to attack the 
covalent enzyme-DNA phosphotyrosine bond with any level of efficiency (153,171). 
 Therefore, to determine whether topoisomerase II is able to rejoin cleaved 
phosphorothiolate oligonucleotides, reactions were terminated with either EDTA or 0.5 
M NaCl prior to the addition of SDS. It is believed that Mg(II), which is essential for 
both cleavage and ligation, can be chelated by EDTA only after ligation has taken place. 
Consequently, treatment with EDTA allows ligation to take place but prevents re-
cleavage (62,157). Similarly, treatment with high salt allows ligation, but promotes 
dissociation of topoisomerase II from the DNA after it is no longer covalently attached to 
the nucleotide substrate. Once again, this leads to a unidirectional closure of the cleaved 
oligonucleotide (61,157). As expected, when wild-type site 1 (not shown) or site 2 
(Figure 13, left panel inset) oligonucleotide was used as substrate, termination of a 30 
min DNA scission reaction with EDTA or NaCl led to a significant reduction in the level 
of cleaved products. For example, greater than 90% of the cleaved oligonucleotides were 
ligated following a 5-min incubation with 0.5 M NaCl. 
 In marked contrast, no decrease in cleaved products was seen in parallel reactions 
that employed either site 1 (not shown) or site 2 (Figure 13, left panel) phosphorothiolate 
oligonucleotide, even when incubation periods in EDTA or NaCl were extended to 30 
min (not shown). Furthermore, time courses for 30-min DNA cleavage reactions 
terminated with SDS, EDTA, or NaCl were essentially superimposable. These findings 
provide strong evidence that human topoisomerase II is incapable of ligating 3’-bridging 
phosphorothiolate cleavage products with any appreciable level of efficiency. Thus, 3’- 
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Figure 13: Reversibility of DNA cleavage mediated by topoisomerase II. Left panel, a 
time course is shown for cleavage of the site 2 oligonucleotide containing a 3’-bridging 
phosphorothiolate at the scissile bond (T/BS*; see Figure 10 for nomenclature). Reactions 
were terminated with SDS (closed circles), EDTA (open circles), or NaCl (open 
triangles). Left panel inset, cleavage of the wild-type site 2 oligonucleotide containing an 
O-P linkage at the scissile bond (T/BO*). A 30-min reaction terminated with SDS, EDTA, 
or NaCl is shown. Right panel, a time course is shown for cleavage of the site 2 suicide 
substrate containing a nick (N) between the +2 and +3 positions on the top strand 
(TN+2/+3/BO*). Reactions were terminated with SDS (closed squares), EDTA (open 
squares), or NaCl (30-min time point, closed triangle). Error bars represent the standard 
error of the mean of two independent experiments or the standard deviation of three 
independent experiments. 
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 -bridging phosphorothiolates allow the forward DNA scission reaction of topoisomerase 
II to be studied in isolation from the ligation event. 
 
Cleavage of Suicide Substrates by Topoisomerase II Is Reversible  
 The only other substrates that are believed to promote a unidirectional topoisomerase 
II-mediated DNA cleavage reaction are known collectively as “suicide substrates.” These 
systems trap cleavage complexes by utilizing nucleic acid molecules that contain non-
contiguous (i.e., nicked) DNA (164), double strand/single strand junctions (160,161,163), 
or unusual secondary structure (i.e., hairpins) (159,162). When suicide substrates are cut 
by topoisomerase II, a segment of the cleaved DNA is able to dissociate from the active 
site, rendering the enzyme unable to ligate the original substrate (161). This process 
results in a time-dependent accumulation of cleavage complexes. 
 One obvious advantage of 3’-bridging phosphorothiolates over “traditional” suicide 
substrates is that the former are composed of intact duplex B-form DNA molecules. More 
importantly, evidence with a hairpin molecule suggests that topoisomerase II actually 
establishes a short-lived cleavage/ligation equilibrium with suicide substrates prior to the 
dissociation event (162). If this is the case, then the use of these substrates to monitor the 
forward scission reaction may not be appropriate. 
 Therefore, to compare cleavage of an S-P linkage to that of a traditional suicide 
substrate, a site 2 oligonucleotide containing a nick between the +2 and +3 positions of 
the top strand was synthesized. In contrast to scission of the intact wild-type substrate, 
which reached cleavage/ligation equilibrium within 5 min, cleaved products of the nicked 
oligonucleotide accumulated throughout the 30 min time course when the reaction was 
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terminated with SDS (Figure 13, right panel). This finding demonstrates that the nicked 
oligonucleotide acts as a suicide substrate for topoisomerase II.  
 To examine the ability of the human enzyme to ligate the nicked suicide substrate, a 
parallel time course for scission was terminated with EDTA. As seen in Figure 13 (right 
panel) cleavage levels were significantly lower in the EDTA-treated reactions. A similar 
result was observed when a 30 min reaction was terminated by the addition of 0.5 M 
NaCl (see indicated data point in Figure 13, right panel). These findings indicate that a 
significant proportion of the initial cleavage complexes formed with the suicide substrate 
are reversible. 
 It is notable that the relative fraction of cleavage complexes that was irreversible 
(i.e., not ligated following treatment with EDTA) rose over time. While levels of 
irreversible cleavage with the suicide substrate represented only ~10% of the total 
scission observed at 1 min, they increased to ~50% by 20-30 min. This result provides 
further evidence that suicide substrates (at least the nicked substrate employed in the 
present study) require a time-dependent conversion from a reversible cleavage complex 
to an irreversible DNA strand break. Presumably, this conversion reflects the point at 
which the non-covalent cleavage product dissociates from topoisomerase II. 
 Thus, while traditional suicide substrates represent an important system to 
accumulate topoisomerase II-DNA cleavage complexes and to provide starting material 
for unidirectional ligation assays, they do not segregate the forward enzyme-mediated 
DNA scission reaction from the cleavage/ligation equilibrium. Consequently, the use of 
these substrates to analyze the forward cleavage reaction of topoisomerase II may lead to 
erroneous mechanistic conclusions.  
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Coordination Between the Two Protomer Subunits of Human Topoisomerase II During 
DNA Cleavage 
 
 Although topoisomerase II must generate a double-stranded nucleic acid break in 
order to carry out the DNA passage reaction, results from numerous laboratories indicate 
that the two protomer subunits of eukaryotic type II enzymes do not cleave and ligate 
DNA in a totally concerted fashion. For example, it has long been known that equilibrium 
levels of DNA strand breaks at the two scissile bonds of a cleavage site (60,61,71,181) 
and rates of ligation of the two strands are often different (60). Furthermore, alterations of 
base sequence (or the inclusion of abasic sites) that have a direct affect on rates of 
ligation of one strand have little effect on rates of ligation of the other strand (33,168). 
Finally, changes in base sequence that enhance the ability of etoposide to inhibit ligation 
at one scissile bond have no significant effect on rates of ligation at the opposite scissile 
bond (72). 
 The above notwithstanding, the same alterations in DNA sequence that specifically 
enhance the ability of etoposide to inhibit ligation at one scissile bond lead to a modest 
increase in topoisomerase II-generated double-stranded breaks at that cleavage site (72). 
This finding implies that there may be some communication between the protomer 
subunits of the human enzyme during the DNA cleavage event, even though there 
appears to be little coordination during ligation. 
 To address the issue of subunit communication, levels of cleavage on the top strand 
of site 1 and site 2 were monitored in the absence or presence of a 3’-bridging 
phosphorothiolate on the bottom strand (see Figure 10). As expected, when situated 
opposite a wild-type O-P scissile bond, rapid DNA cleavage/ligation equilibria 
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characterized by low levels of scission were established on the top strand of both sites. 
However, when situated opposite an S-P scissile bond that did not allow ligation, levels 
of cleavage on the top strand of both sites were ~5– to 7–fold higher as compared to 
comparable wild-type substrates and rose over the course of the assay. Moreover, the 
time courses for the accumulation of DNA breaks on the top strands paralleled those seen 
for the bottom S-P strands.  
 These results indicate that there is at least some level of coordination between the 
two protomer active sites of topoisomerase II. However, since levels of cleavage on the 
strand opposite the S-P bond were several–fold lower than observed on the 
phosphorothiolate-containing strand, it is clear that DNA cleavage by the two protomer 
subunits does not take place in a completely concerted fashion. 
 The partial coordination between the protomer subunits of topoisomerase II may be 
explained by at least three independent mechanisms that are not mutually exclusive. First, 
cleavage of one scissile bond may decrease the ability of the enzyme to ligate the 
opposite scissile bond. This possibility seems unlikely, as it would provide no benefit to 
the catalytic reaction of topoisomerase II. In addition, previous studies have found little 
coordination between the protomer subunits of topoisomerase II during ligation 
(33,60,72). However, as a control, the rate of ligation of the top strand of site 2 was 
determined when it was situated opposite an O-P or an S-P scissile bond (Figure 14). As 
predicted, rates of ligation of the two substrates were comparable.  
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Figure 14: Time course for topoisomerase II-mediated ligation of the wild-type top 
strand of the site 2 oligonucleotide. Site 2 substrates containing either a wild-type O-P 
linkage (T*/BO, open squares) or phosphorothiolate S-P linkage (T*/BS, closed squares) 
at the scissile bond of the bottom strand were employed. The total percent cleavage prior 
to initiation of ligation was set to 100%. Error bars represent the standard deviation of at 
least three independent experiments. 
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 Second, trapping a cleavage complex at one scissile bond should increase the 
concentration of enzyme that contains the opposite scissile bond in its active site. Since 
levels of cleavage are directly proportional to levels of topoisomerase II-DNA binding, 
this effect could account for the enhanced scission on the opposite strand. This 
mechanism requires no alteration in the forward rate of scission and is consistent with the 
finding that the accumulation of breaks on the top strand of site 1 and site 2 paralleled 
that seen for the bottom S-P strands (Figure 10).  
 Third, cleavage at one scissile bond may increase the rate of cleavage at the opposite 
scissile bond. As a first attempt to address this hypothesis, a site 2 oligonucleotide that 
contained a nick at the scissile bond (-1/+1 position) of the top strand was employed as a 
model of a DNA substrate that had already been cut on one of its two strands. It should 
be noted, however, that the nicked oligonucleotide is not covalently attached to 
topoisomerase II. Thus, it is unclear whether this substrate adequately mimics an enzyme-
DNA cleavage complex in which one of the two strands has been cut by topoisomerase 
II. 
 With the above caveat in mind, the ability of topoisomerase II to cleave the bottom 
strand of site 2 was monitored when the top scissile bond was either intact or nicked 
(Figure 15). The initial experiment utilized a substrate that contained a wild-type O-P 
linkage at the scissile bond of the bottom strand. Two observations were noted. First, 
levels of cleavage of the bottom strand increased ~20–fold when situated opposite a 
nicked top strand. Second, the concentration of cleavage complexes reached a rapid 
equilibrium and did not rise over the time course of the experiment. This result indicates  
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Figure 15: Topoisomerase IImediated cleavage of a substrate containing a nick at one 
scissile bond. Time courses are shown for the following site 2 substrates: oligonucleotide 
containing an intact top strand and a wild-type O-P linkage at the scissile bond of the 
bottom strand (T/BO*, open circles); oligonucleotide containing a nick at the scissile 
bond (–1/+1 position) of the top strand and a wild-type O-P linkage at the scissile bond of 
the bottom strand (TN-1/+1/BO*, open squares); oligonucleotide containing an intact top 
strand and a phosphorothiolate S-P linkage at the scissile bond of the bottom strand 
(T/BS*, closed circles); and oligonucleotide containing a nick at the scissile bond of the 
top strand and a phosphorothiolate S-P linkage at the scissile bond of the bottom strand 
(TN-1/+1/BS*, closed squares). Error bars represent the standard deviation of at least three 
independent experiments. 
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that unlike the nicked +2/+3 substrate utilized in Figure 13, the nicked scissile bond (-
1/+1) oligonucleotide did not act as a suicide substrate for topoisomerase II.  
 To determine whether the enhanced cleavage observed when a wild-type strand was 
situated opposite a nicked scissile bond reflected an increase in the forward rate of DNA 
cleavage, the experiment was repeated using a site 2 substrate that contained a 3’-
bridging phosphorothiolate at the scissile bond of the bottom strand (Figure 15). When 
situated opposite the nicked strand, the rate of cleavage of the bottom S-P scissile bond 
rose considerably. Although rates were too rapid to measure accurately, it appears that 
they increased several–fold. These data imply that cleavage on one strand by 
topoisomerase II has the capacity to increase the rate of cleavage on the opposite strand. 
Whether the increased rate of scission reflects a change in the conformation of the DNA, 
the enzyme, or a combination of both remains to be determined. 
 Taken together, the above studies suggest that at least two mechanisms may 
contribute to the partial coordination between the two subunits of topoisomerase II: 
increased concentration of the second scissile bond in the active site of the enzyme and 
an enhanced rate of scission of the second strand following cleavage of the first. This 
issue is addressed in greater detail in Chapter IV. 
 
Effect of ATP on the Forward DNA Scission Reaction of Human Topoisomerase II  
 For topoisomerase II-mediated DNA strand passage to occur, both strands of the 
“gate” segment must be cleaved (5,8,22,26,27,44). ATP binding (one molecule per 
topoisomerase II protomer) induces opening of the DNA gate (5,8,22,26,27,29,44,182,183), 
and it is believed that hydrolysis of one of the ATP molecules enhances the rate of strand 
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passage (184). Several laboratories have demonstrated that levels of topoisomerase II-
DNA cleavage complexes rise in the presence of the high-energy cofactor 
(5,8,22,26,27,44). Although the mechanistic basis for this observation is not known, one 
study reported that rates of DNA ligation were slowed in the presence of the non-
hydrolyzable ATP analog APP(NH)P (166). To determine whether ATP has an effect on 
the forward DNA scission reaction of human topoisomerase II, the ability of the enzyme 
to cleave the 3’-bridging phosphorothiolate substrate (site 2) in the presence and absence 
of the nucleotide triphosphate was compared. As seen in Figure 16, ATP had virtually no 
effect on the rate of DNA scission. Therefore, it is concluded that the increased 
concentration of cleavage complexes seen in the presence of ATP is not due to an 
enhanced forward rate of cleavage. 
 
Dependence of the Forward Scission Reaction of Topoisomerase II on DNA Length  
 A previous study demonstrated that the ability of human topoisomerase II and 
chlorella virus topoisomerase II to form cleavage complexes was dependent on the length 
of the DNA substrate (150). Consistent with the footprint of topoisomerase II on DNA 
(~28 bp) (185), a minimal requirement for a 20-bp oligonucleotide was noted and 
substantial scission was not seen until a substrate of ~40 bp was employed. Levels of 
cleavage complexes did not correlate with changes in binding affinity (150). 
Consequently, they must be due to a change in the ability of topoisomerase II to either 
cleave or ligate short substrates. 
 To determine whether the effect of DNA length on cleavage complex formation was 
due to a decreased ability to cleave short substrates, a series of nested site 2 
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Figure 16: Topoisomerase II-mediated DNA cleavage in the presence of ATP. A time 
course is shown for cleavage of the site 2 substrate containing a phosphorothiolate S-P 
linkage at the scissile bond of the bottom strand (T/BS*) in the absence (-ATP, closed 
circles) or presence of ATP (+ATP, open circles). Error bars represent the standard 
deviation of at least three independent experiments. 
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oligonucleotides with 3’-bridging phosphorothiolates at the scissile bond of the bottom 
strand was synthesized (Figure 17, left panel). As found previously with wild-type 
substrates, phosphorothiolate substrates displayed virtually no cleavage with the 20-mer, 
and low levels were seen with the 25- and 30-mer. A modest rise in cleavage was 
observed when substrate length was increased to 40 bp, followed by a dramatic rise when 
it was increased to 50 bp (the length of the parent oligonucleotide). These data indicate 
that the DNA length dependence of topoisomerase II is due to an effect on the forward 
scission reaction and imply that protein-DNA contacts outside of the active site of the 
enzyme may be required to promote cleavage.  
 Although topoisomerase II can sense the length of its substrate, only the central 
portion of the DNA needs to be duplex (Figure 17, right panel). When the nested 
oligonucleotides containing the S-P linkage at the scissile bond were annealed with the 
parental wild-type 50-mer top strand, a substantial increase in cleavage was observed as 
the length of the bottom strand was increased.  
 
Effects of Topoisomerase II Poisons on the Forward DNA Cleavage Reaction of Human 
Topoisomerase II  
 
 Topoisomerase II poisons increase the concentration of cleavage complexes by two 
non-mutually exclusive mechanisms. Anticancer drugs, such as etoposide and amsacrine, 
strongly inhibit the ability of the enzyme to ligate cleaved DNA substrates 
(72,94,165,166,186,187). Because of their affect on ligation, it has been assumed that 
these agents have no significant effect on the forward scission reaction. In contrast, DNA 
lesions that poison topoisomerase II, such as abasic sites, have little effect on rates of 
ligation (64,135,136,156,163). Consequently, it has been assumed that they act primarily 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Effect of oligonucleotide length on DNA cleavage mediated by topoisomerase 
II. Left panel, time courses are shown for cleavage of the phosphorothiolate-containing 
bottom strand of nested site 2 substrates. Reactions were monitored with 50-mer (closed 
circles), 40-mer (closed squares), 30-mer (open circles), 25-mer (open squares), or 20-
mer (closed diamonds) duplex substrates. Right panel, time courses are shown for 
cleavage of the phosphorothiolate-containing bottom strand of nested site 2 substrates 
containing a 50-mer top strand and a 50-mer (closed circles), 40-mer (closed squares), 
30-mer (open circles), 25-mer (open squares), or 20-mer (closed diamonds) bottom 
strand. Error bars represent the standard deviation of at least three independent 
experiments. 
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 by enhancing the forward rate of DNA scission. Unfortunately, it has not been possible 
to test these assumptions directly. Therefore, the ability of these topoisomerase II poisons 
to alter the rate of DNA scission was characterized using the phosphorothiolate 
substrates. 
 The effects of etoposide and amsacrine on the forward rate of cleavage of site 1 and 
site 2 are shown in Figures 18 and 19, respectively. In all cases, the drugs increased the 
concentration of cleavage complexes when wild-type oligonucleotides were employed. 
However, virtually no increase in the rate of scission was observed when 3’-bridging 
phosphorothiolate substrates were examined. These data strongly suggest that etoposide 
and amsacrine increase levels of topoisomerase II-DNA cleavage complexes primarily 
by inhibiting enzyme-mediated ligation. 
 As discussed above, suicide substrates establish a short-lived DNA cleavage/ligation 
equilibrium before irreversibly trapping cleavage complexes. Consequently, their use as a 
model for the forward topoisomerase II DNA cleavage reaction was questioned. For 
example, if etoposide inhibits enzyme-mediated ligation prior to the “suicidal” 
dissociation of the non-covalent DNA cleavage product, the drug could increase levels of 
trapped cleavage complexes independent of any effect on the forward rate of scission. To 
address this critical point, the effect of etoposide on the ability of topoisomerase II to 
cut the nicked suicide substrate described in Figure 13 was characterized (Figure 18, 
lower panel). Despite the fact that etoposide does not increase the forward rate of DNA 
scission, a dramatic rise in cleavage complexes was observed when the drug was included 
in reactions with the suicide substrate. This finding underscores the need to exercise 
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Figure 18: Effect of etoposide on the forward rate of topoisomerase II-mediated DNA 
scission. Time courses for cleavage of the bottom strand of the site 1 (left panel) and site 
2 (right panel) substrates are shown for oligonucleotides containing a wild-type O-P 
linkage at the scissile bond of the bottom strand (T/BO*) and oligonucleotides containing 
a phosphorothiolate S-P linkage at the scissile bond of the bottom strand (T/BS*) in the 
absence (T/BO*, open circles; T/BS*, closed circles) or presence (T/BO* + Etop, open 
squares; T/BS* + Etop, closed squares) of 50 μM etoposide. The bottom panel shows 
time courses for cleavage of the bottom strand of the site 2 suicide substrate containing a 
nick at the +2/+3 position of the top strand in the absence (TN+2/+3/BO*, open triangles) or 
presence (TN+2/+3/BO* + Etop, closed triangles) of 50 μM etoposide. Error bars represent 
the standard error of the mean of two independent experiments or the standard deviations 
of at least three independent experiments. 
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Figure 19: Effect of amsacrine on the forward rate of topoisomerase II-mediated DNA 
scission. Time courses for cleavage of the bottom strand of the site 1 (left panel) and site 
2 (right panel) substrates are shown for oligonucleotides containing a wild-type O-P 
linkage at the scissile bond of the bottom strand (T/BO*) and oligonucleotides containing 
a phosphorothiolate S-P linkage at the scissile bond of the bottom strand (T/BS*) in the 
absence (T/BO*, open circles; T/BS*, closed circles) or presence (T/BO* + AMSA, open 
squares; T/BS* + AMSA, closed squares) of 50 μM amsacrine. Error bars represent the 
standard deviation of at least three independent experiments. 
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caution when drawing mechanistic conclusions about the forward rate of DNA cleavage 
based on the results obtained with suicide substrates. 
 Finally, when abasic sites are situated within the 4-bp region located between the 
two scissile bonds, their presence raises the concentration of topoisomerase II-DNA 
cleavage complexes (64,136,156,164). As seen in Figure 20, the inclusion of an abasic 
site at the +1 position of the top strand of site 1 or site 2 increased levels of cleavage 
complexes several–fold when substrates with wild-type O-P scissile bonds were used. In 
contrast to the anticancer drugs, which had little effect on the forward cleavage reaction, 
the abasic site stimulated the rate of DNA scission of substrates with S-P scissile bonds 
~2– to 3–fold (Figure 20). Similar results were seen with substrates that contained an 
abasic site at the +2 or +4 position (not shown). These findings confirm the assumption 
that abasic sites act by stimulating the forward rate of topoisomerase II-mediated DNA 
scission. 
 
Conclusions  
 Despite the importance of DNA cleavage to the cellular functions of type II 
topoisomerases and their role as targets for anticancer drugs, the tight coupling of the 
cleavage/ligation equilibrium has made it difficult to characterize the mechanism by 
which these enzymes cut the genetic material. To uncouple the forward DNA scission 
reaction of human topoisomerase II from the ligation event, a novel system that utilized 
3’-bridging phosphorothiolates at the scissile bonds of well-defined topoisomerase II-
DNA cleavage sites was developed. Cleavage of these substrates appeared to be 
irreversible, resulting in a unidirectional enzyme-mediated DNA scission 
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Figure 20: Effect of an abasic site on the forward rate of topoisomerase II-mediated 
DNA scission. Time courses are shown for the following site 1 (left panel) and site 2 
(right panel) substrates: oligonucleotide containing a wild-type top strand and a wild-type 
O-P linkage at the scissile bond of the bottom strand (T/BO*, open circles); 
oligonucleotide containing an abasic (AP) site at the +1 position of the top strand and a 
wild-type O-P linkage at the scissile bond of the bottom strand (T+1AP/BO*, open 
squares); oligonucleotide containing a wild-type top strand and a phosphorothiolate S-P 
linkage at the scissile bond of the bottom strand (T/BS*, closed circles); and 
oligonucleotide containing an abasic site at the +1 position of the top strand and a 
phosphorothiolate S-P linkage at the scissile bond of the bottom strand (T+1AP/BS*, closed 
squares). Error bars represent the standard deviation of at least three independent 
experiments. 
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 reaction. The use of oligonucleotides with 3’-bridging phosphorothiolates provided 
critical information on the coordination of the protomer subunits of topoisomerase II 
and the mechanism of action of topoisomerase II poisons. These substrates will be a 
valuable resource for future studies on DNA scission and the topoisomerase II-DNA 
cleavage complex. 
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CHAPTER IV 
 
COORDINATING THE TWO PROTOMER ACTIVE SITES OF HUMAN 
TOPOISOMERASE II: NICKS AS TOPOISOMERASE II POISONS 
 
 
Introduction 
 Given the central nature of the DNA cleavage reaction to the physiological and 
pharmacological functions of topoisomerase II, it is important to understand the 
mechanistic details of this process. In this regard, it has long been known that type II 
topoisomerases generate two “coordinated” nicks on the opposite strands of the double 
helix as opposed to one “unified” double-stranded DNA break. Evidence for a 
coordinated mechanism stems from the findings that levels of scission on the opposite 
strands of a cleavage site are often non-equal (61) and that the enzyme religates the two 
strands of cleaved molecules in a sequential fashion (60). Under equilibrium conditions, 
~0.5–1% of human topoisomerase II in a scission reaction mixture exists as a covalent 
enzyme-cleaved DNA complex (188) [Figure 21]. Approximately half of these 
complexes contain double-stranded breaks with the remainder containing single-stranded 
DNA breaks. This finding suggests that every time the enzyme cuts one strand of the 
double helix, it goes on to cut the second strand a high proportion of the time. If the 
enzyme cut the two strands of DNA in a completely non-coordinated fashion, virtually no 
double-stranded breaks would be generated (1% cleavage of the first strand x 1% 
cleavage of the second strand  0.01% double-stranded breaks). Thus, there must be a 
relatively high degree of coordination between the two protomer active sites of 
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Figure 21: Coordination between protomer halves during plasmid DNA cleavage. An 
agarose gel from a topoisomerase II-DNA cleavage reaction in the absence (DNA) or 
presence (TII) of topoisomerase II is shown at left. The enzyme:plasmid ratio used for 
this experiment was 40:1. Supercoiled (F I), nicked (F II), and linear (F III) plasmid 
bands are denoted. The proportion of nicked plasmids (containing single-stranded breaks, 
SSB) and linear plasmids (containing double-stranded breaks, DSB) generated by 
topoisomerase II-mediated DNA cleavage (out of a total of 1.0) is shown at right. Error 
bars represent the standard deviation three or more independent experiments. 
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 topoisomerase II, even if they do not act in complete concert. Consistent with the above 
conclusion, once topoisomerase II cleaves the first strand, it cuts the second strand at a 
rate that is >10–fold faster (70). However, the mechanism that underlies the enhanced 
cleavage of the second strand is not known.  
 It is notable that the nucleic acid substrates for first and second strand cleavage are 
not equivalent. Unlike the former substrate, which is an intact duplex, the latter contains a 
nick at one of the scissile bonds. Consequently, the previous chapter proposed that human 
topoisomerase II generates a high proportion of double-stranded DNA breaks because 
nicked molecules are a more efficient substrate for the enzyme as shown in Figure 15. To 
this point, equilibrium levels of cleavage on one strand of an oligonucleotide that 
contains a nick at the scissile bond on the opposite strand are >20–fold higher than those 
generated by the enzyme with the equivalent intact duplex (see Figures 24 and 25 
discussed below). The present chapter explores the possible role of nicks in coordinating 
DNA cleavage by the two protomer subunits of topoisomerase II. 
 
Results and Discussion 
 
Coordination of the Two Protomer Subunits of Topoisomerase II 
 To more fully assess the potential of nicks to coordinate the two protomer active 
sites of topoisomerase II during DNA scission, the kinetics of cleavage of an intact 
substrate and an equivalent oligonucleotide that contained a nick at one of the scissile 
bonds were studied by rapid chemical quench. Reactions followed cleavage of the strand 
opposite the nick over a time course from 5 ms to 3 s (Figure 22, left panel). Mg
2+
 or  
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Figure 22: A nick at the scissile bond enhances the forward rate of DNA cleavage of 
topoisomerase II. Left panel, rapid time courses for reactions in the presence of 
topoisomerase II. Reactions were followed up to 3 s (plots are shown to 2 s) with un-
nicked duplex (wild-type, WT; red) substrates in the presence of Mg
2+
 (open circles) or 
Mn
2+
 (open squares) or scissile bond nicked (-1/+1 position, blue) substrates in the 
presence of Mg
2+
 (closed circles) or Mn
2+
 (closed squares). Data were best fitted by 
double exponential curves (see Chapter III). Right panel, topoisomerase II ligation 
reactions were performed with un-nicked duplex  (wild-type, WT; open circles, red) or 
scissile bond nicked (closed circles, blue) substrates. Total percent DNA cleavage was set 
to 100% at time zero. Error bars represent the standard error of the mean of two 
independent experiments or the standard deviation three or more independent 
experiments. 
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Mn
2+
 was used as the required divalent cation in these experiments. Although Mg
2+
 most 
likely represents the physiological divalent metal ion, higher rates and levels of cleavage 
are observed in the presence of Mn
2+
 (see Chapter V). With either metal ion, initial 
velocities of cleavage mediated by topoisomerase II were 10– to 20–fold higher with the 
nicked as compared to the duplex substrate. Initial velocities for cleavage of the nicked 
and duplex substrates in the presence of Mg
2+
 were 110 ± 5.6 and 7.8 ± 2.4 s
-1
, 
respectively, and in the presence of Mn
2+
 were 230 ± 12 and 9.4 ± 1.3 s
-1
, respectively. 
Taken together, these data suggest that the rate of cleavage increases dramatically (~15– 
to 25–fold) in the presence of a nick. 
 Levels of topoisomerase II-generated DNA strand breaks can be raised either by 
increasing the forward rate of cleavage or by inhibiting the backward rate of ligation 
(8,94). Most clinically relevant topoisomerase II-targeted drugs act by the latter 
mechanism (8). However, if DNA nicks are being used to coordinate the two protomer 
active sites of human topoisomerase II during the cleavage reaction, they should act 
primarily on the forward rate of scission. To determine whether this is the case, the effect 
of a nicked scissile bond on the rate of enzyme-mediated DNA ligation of the opposite 
strand was assessed. As seen in Figure 22 right panel, time courses for ligation of the 
duplex and nicked oligonucleotides were indistinguishable. The apparent first order rate 
constants for the duplex and nicked substrates were 0.031 ± 0.0079 and 0.036 ± 0.0074 s
-1
, 
respectively. Together with the kinetic data discussed above, these results indicate that 
the introduction of a nick at one scissile bond greatly stimulates the forward rate of 
scission of the second strand by topoisomerase II. 
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 Why does topoisomerase II preferentially cleave nicked DNA? Structural studies 
provide insight into this important mechanistic question. Recently, the crystal structure of 
the catalytic core of yeast topoisomerase II complexed with DNA was solved (65). The 
complex was non-covalent in nature, and the substrate contained nicks at both scissile 
bonds. Surprisingly, DNA in the active site of the enzyme was markedly reshaped, with 
its trajectory being bent by ~150º (65) (Figure 23). Considerable distortion was observed 
within the double helix, such that the bases between the scissile bonds existed as A-form 
rather than B-form DNA. Strain was observed over ~16 base pairs of the DNA cleavage 
site, and the highest degree of strain, as determined by the degree of deviation of twist 
from B-form DNA, occurred at the scissile bonds on each strand of the double helix.  
 It is reasonable to assume that the acute bending of the double helix seen in the 
crystal structure approximates the transition state of the nucleic acid substrate during 
cleavage by topoisomerase II. Given the high degree of distortion and strain required for 
the transition state, it is difficult for intact duplex DNA to attain this structure. Therefore, 
we propose that once the enzyme has cut the first strand of the double helix, the increased 
conformational flexibility that results from the nick greatly facilitates the conversion to 
the cleavage transition state. As a result, scission of the second strand by topoisomerase II 
occurs at a considerably faster rate, effectively coordinating the two protomer subunits of 
the enzyme. 
 Consistent with this proposal, DNA lesions (such as abasic sites or alkylated bases) 
that distort, bend, or increase the flexibility of the double helix are highly effective 
topoisomerase II poisons when located between the scissile bonds. To this point, DNA 
lesions often increase enzyme-mediated DNA cleavage >10–fold (64,133,136). 
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Figure 23: Topoisomerase II severely bends DNA. The non-covalent complex between 
yeast topoisomerase II and DNA is partially shown above. The double helix colored 
orange is bent when bound in the active site of topoisomerase II. Figure adapted from ref. 
(65).  
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Furthermore, they stimulate the forward rate of scission without inhibiting ligation 
(64,133,136). 
 If the hypothesis discussed above is correct, the presence of a nick in the vicinity of 
the scissile bonds should enhance the flexibility of the double helix and promote DNA 
cleavage by topoisomerase II. However, since DNA strain is greatest at the scissile 
bonds, placement of a nick precisely at the point of cleavage on one strand should have 
the greatest effect on cleavage of the opposite strand. Consequently, the relationship 
between the position of the nick and levels of DNA scission by topoisomerase II was 
determined. As seen in Figure 24, the presence of a nick in the vicinity of the scissile 
bond generally increased equilibrium levels of cleavage at the opposite scissile bond ~2– 
to 6–fold. Moreover, the presence of a nick at the scissile bond (-1/+1 position) increased 
cleavage at the opposite scissile bond ~25–fold. Results from DNA cleavage time courses 
demonstrated that the increase in DNA cleavage levels, as compared to wild-type, occurs 
quickly (Figure 25). These findings demonstrate that increased DNA flexibility enhances 
the ability of topoisomerase II to cleave its substrate. The fact that the increase in 
cleavage was dramatically higher when the nick was placed directly at the scissile bond 
further supports the proposal that coordination of the two protomer subunits of 
topoisomerase II results from an enhanced DNA conformational flexibility that follows 
scission of the first strand. 
 
Nicks as Topoisomerase II Poisons 
 In addition to stimulating cleavage at the “native” site, the presence of a nick at a 
position other than that of the scissile bond always generated a novel DNA cleavage band  
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Figure 24: A nick at one scissile bond greatly enhances DNA cleavage at the scissile 
bond on the opposite strand. The sequence of the central region of the 50-mer 
oligonucleotide cleavage substrate, along with the positions of the scissile bonds (arrows) 
is show at top. Levels of topoisomerase II-mediated DNA cleavage at the native scissile 
bond on the bottom strand are shown for the un-nicked oligonucleotide (wild-type, WT) 
and for substrates containing a nick at the indicated position on the top strand (-2/-3, -1/-
2, -1/+1, +1/+2, +2/+3, +4/+5). Cleavage for un-nicked and scissile bond nicked (-1/+1) 
substrates are depicted in black. Error bars represent the standard deviation of at least 
three independent experiments. 
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Figure 25: Time courses for topoisomerase II-mediated cleavage of nicked substrates. 
The sequence of the central region of the 50-mer oligonucleotide cleavage substrate, 
along with the positions of the scissile bonds (arrows) is show at top. Levels of 
topoisomerase II-mediated DNA cleavage on the bottom strand were monitored over 30 
min for the un-nicked oligonucleotide (WT, black open circles) and for substrates that 
contained a nick at the indicated position of the top strand (-2/-3, blue open squares; -1/-
2, orange closed squares; -1/+1, black closed circles; +1/+2, gold open triangles; +2/+3, 
purple closed triangles; and +4/+5, green open diamonds). Error bars represent the 
standard deviation of at least three independent experiments. 
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on the opposite strand that was 4 base pairs away from the nick (such that cleavage 
generated a 4-base 5’-overhang). Cleavage levels at these novel sites were at least 
equivalent to that seen at the native site, and in some cases were as much as 6–fold higher 
(Figure 26). 
 To further investigate the ability of nicks to induce enzyme-mediated cleavage at 
novel DNA sites, an oligonucleotide substrate that contained no native sites for 
topoisomerase II was utilized. No appreciable level of DNA scission was detected with 
this substrate in the absence of nicks (Figure 27). Nicks were introduced at single sites on 
one strand of the double helix and cleavage on the opposite strand was characterized 
(Figure 27). In all cases, a novel cleavage site located 4 bases away from the nick was 
generated. These novel sites all had different sequences, with nicks 1, 2, and 3 inducing 
cleavage between GA, TC, and CG to give products of 25, 21, and 17 bases, respectively. 
Levels of DNA cleavage were at least comparable to that observed with the native site 
shown in Figure 24 (0.29%, indicated by the dashed line) and ranged as much as 6–fold 
higher (Figure 27).  
 The above findings demonstrate that nicks, like other DNA lesions, are 
topoisomerase II poisons. However, they differ from the actions of other lesions in a 
significant fashion. Abasic sites and modified bases are site-specific topoisomerase II 
poisons that only stimulate cleavage when they are located between the two scissile 
bonds of a pre-existing site of enzyme action (64,133,136). Furthermore, while they 
enhance scission at the native site, they do not generate novel sites of cleavage 
(64,133,136). In contrast, the actions of nicks are not constrained to pre-existing sites of  
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Figure 26: Nicks generate novel DNA cleavage sites for topoisomerase II. In addition to 
stimulating cleavage at the “native” site, the presence of a nick at a position other than 
that of the scissile bond always generated a novel DNA cleavage band on the opposite 
strand that was 4 base pairs away from the nick (such that cleavage generated a 4-base 5’-
overhang). The position of the native scissile bond is between the -1 and +1 nucleotides. 
Topoisomerase II-mediated DNA cleavage levels on the bottom strand are shown for 
the un-nicked (WT) oligonucleotide and a substrate that contained a nick (-1/+1) at the 
native scissile bond on the bottom strand (red bars). Enzyme-mediated DNA cleavage of 
substrates that contained a nick located at other positions on the top strand (-2/-3, -1/-2, 
+1/+2, +2/+3, +4/+5) was monitored four base pairs away on the bottom strand (open 
bars). Error bars represent the standard deviation of at least three independent 
experiments. 
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Figure 27: Nicks poison topoisomerase II. Nicks were incorporated into the top strand 
of a 50-mer oligonucleotide (partially shown at top) that did not display any native 
cleavage sites. Substrates contained a nick at one of three different positions (Nick 1, 2, 
or 3), and DNA cleavage on the opposite strand was monitored. Cleavage at the 
corresponding sites in the un-nicked (wild-type, WT) substrate is shown for comparison. 
The approximate level of DNA cleavage generated at a typical un-nicked native site 
(0.29%, see Figure 24) is represented by the dashed line. Error bars represent the standard 
deviation of at least three independent experiments. 
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topoisomerase II action. The mere presence of a nick in duplex DNA is sufficient to 
create a novel cleavage site for human topoisomerase II. 
 
Conclusions 
 In summary, nicks have a profound effect on the DNA cleavage activity of 
topoisomerase II. The presence of a nick at one scissile bond dramatically increases the 
rate of cleavage at the scissile bond on the opposite strand of the double helix. We propose 
that nicks trigger faster rates of scission by introducing flexibility in the DNA substrate 
that allows it to attain the acutely bent transition state that is required for efficient 
cleavage. This enhanced activity at the second strand coordinates the two protomer 
subunits of topoisomerase II during the DNA cleavage reaction and allows the enzyme to 
create double-stranded breaks in the genetic material. Finally, nicks can be added to the 
list of DNA lesions that poison topoisomerase II. This finding may have implications for 
the actions of type II enzymes during apoptotic events. Moreover, it suggests a 
mechanism whereby topoisomerase II may impact the physiological effects of 
endogenous, environmental, or pharmaceutical compounds that damage the genetic 
material. 
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CHAPTER V 
 
HUMAN TOPOISOMERASE II USES A TWO METAL ION MECHANISM FOR 
DNA CLEAVAGE 
 
 
Introduction 
 Despite the importance of topoisomerase II-mediated DNA cleavage to the 
regulation of DNA topology and the treatment of human cancers, many aspects of the 
reaction are poorly understood. To this point, it has long been known that the type II 
enzyme requires a divalent metal ion in order to cleave DNA (30,61,62,157,158), but the 
role of the cation is unclear.  
 Commonly, enzymes that cleave nucleic acids, including exo- and endonucleases, 
utilize divalent cations in their active sites to stabilize both attacking (i.e., amino acids 
and/or water) and leaving groups (i.e., DNA backbone oxygen atoms) (68,189-207). 
However, the number of metal ions per active site and the specific roles of these cations 
in stabilizing leaving groups (bridging vs. non-bridging oxygen) varies. For example, 
based on structural studies, it has been proposed that several DNA polymerases utilize 
two divalent cations for both their 3’->5’ proofreading exonuclease and 5’->3’ 
polymerization reactions (189,192). Kinetic studies with these enzymes suggest that 
interactions between one of the active site divalent cations and the bridging oxygen of the 
DNA backbone play an important role in supporting catalysis (192,195). Although some 
ribozymes utilize two metal ions to catalyze self-splicing, others require only one 
(191,198,208-213). Furthermore, interactions with both the bridging and non-bridging 
oxygens have been described (198,209,212). Finally, structural studies imply that the 
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restriction endonuclease, BglII, uses only a single divalent cation and that it coordinates 
with the non-bridging oxygen of the scissile phosphate (200,214). 
 Based on mutagenesis and enzymological studies with DNA gyrase, Noble and 
Maxwell suggested that the prokaryotic type II topoisomerase utilizes a two metal ion 
mechanism similar to that of DNA polymerases (68). However the specific roles of the 
divalent cations in DNA gyrase were not characterized. 
 Recently, a crystal structure of the catalytic core of yeast topoisomerase II 
complexed with DNA was solved (65). While the structure showed only a single Mg
2+
 
atom per active site, the enzyme-DNA complex was non-covalent in nature. Furthermore, 
it was noted that the active site tyrosine was too far away from the scissile bond to be in a 
cleavage competent configuration (65). Consequently, the number of divalent metal ions 
in the active site of eukaryotic type II topoisomerases and their role(s) in the DNA 
cleavage reaction remain open questions. 
 To resolve these fundamental issues, the present study utilized a series of divalent 
metal ions with varying thiophilicities in conjunction with DNA cleavage substrates that 
replaced the 3’-bridging oxygen of the scissile bond with a sulfur atom (i.e., 3’-bridging 
phosphorothiolates). Results indicate that human topoisomerase II mediates DNA 
cleavage via a two metal ion mechanism and that one of the required divalent cations 
makes critical interactions with the bridging atom of the scissile bond during this process. 
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Results and Discussion 
 
DNA Cleavage Mediated by Human Topoisomerase II Is Promoted by an Interaction 
Between a Divalent Metal Ion and the Bridging Atom of the Scissile Phosphate 
 
 Although the DNA cleavage reaction of human type II topoisomerases is central to 
their physiological functions and their roles as targets for anticancer drugs 
(30,61,62,68,157,158), the mechanism of the reaction has not been fully described. The 
only cofactor required for DNA scission is a divalent metal ion, which appears to be 
Mg
2+
 in vivo (30,62,68,157,158). However, the contribution of the divalent cation to 
enzyme function is not understood. Therefore, the role of the metal ion in the DNA 
cleavage reaction mediated by human topoisomerase II was characterized.  
 Several nucleases that generate a 3’-OH and 5’-phosphate during cleavage require an 
interaction between a metal ion and the 3’-bridging atom of the scissile phosphate 
(193,199). Consequently, as a first step in exploring the requirement for a divalent cation 
in the DNA cleavage reaction of human topoisomerase II, the interaction between the 
divalent cation and the 3’-bridging atom was assessed. Experiments took advantage of 
the novel phosphorothiolate-containing oligonucleotide substrates described in Chapter 
III that substituted a 3’-bridging sulfur for the oxygen atom at the scissile phosphate (i.e., 
S–P scissile bond). Topoisomerase II cleaves these oligonucleotides with all of the 
characteristics of wild-type substrates, with the following exception: since the resulting 
3’-terminal –SH moiety is a poor nucleophile at phosphorous, 3’-bridging 
phosphorothiolates do not support ligation. As a result, these substrates isolate the 
forward DNA scission event from ligation, and therefore allow high levels of cleavage 
complexes to accumulate. This is in contrast to wild-type oligonucleotides with 3’-
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bridging oxygen atoms (i.e., O–P scissile bond), which establish a rapid DNA cleavage-
ligation equilibrium and maintain low levels of cleavage complexes (see Chapter III). 
Due to the characteristics of DNA scission with these substrates, both rates and levels of 
cleavage can be determined with S–P oligonucleotides. However, only levels of cleavage 
can be monitored with O–P oligonucleotides in conventional kinetic experiments. 
 Interactions between the divalent cation and the 3’-bridging atom of the scissile 
phosphate were determined by comparing the ability of topoisomerase II to cleave DNA 
substrates containing either a 3’-bridging oxygen or sulfur atom in the presence of metal 
ions of varying  “softness” (i.e., thiophilicity). The ions that were used for this study were 
Ca
2+
, Mg
2+
, Co
2+
, and Mn
2+
. Within this series, Co
2+
 and Mn
2+
 are the “softest,” or most 
thiophilic metals, and Mg
2+
 and Ca
2+
 are harder, or less thiophilic (215-217). Softer metal 
ions often prefer sulfur over oxygen as an inner-sphere ligand, while hard metals usually 
coordinate more readily with oxygen (192,195,198,208-212,215-217).  
 The DNA cleavage reaction of human topoisomerase II generates a 3’-oxygen 
leaving group in a divalent metal ion-dependent manner. If there is a direct interaction 
between the metal ion and the leaving group that facilitates catalysis, relative rates (or 
levels) of scission with substrates containing a 3’-sulfur in place of the oxygen should 
increase in the presence of soft (thiophilic) metals (192,195,198,208-212). Conversely, 
less cleavage should be generated in reactions that contain hard metals (192,195,198,208-
212). 
 The first set of experiments established the capacity of divalent metal ions to support 
topoisomerase II-mediated cleavage of a wild-type O–P substrate (site 2 
oligonucleotide). Consistent with previous work with plasmid substrates (158), Mn
2+
, 
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Ca
2+
, and Co
2+
 all generated higher levels of DNA cleavage than Mg
2+
 (Figure 28, left 
panel). Levels of cleavage complexes formed in the presence of Mn
2+
 or Ca
2+
 were ~4 
times higher than those observed with Mg
2+
, and those with Co
2+
 were ~2 times higher.  
 The divalent cation preference for reactions that monitored cleavage of the 
equivalent S–P oligonucleotide is shown in the right panel of Figure 28. Rates and levels 
of cleavage observed in the presence of the thiophilic metal ions, Mn
2+
 and Co
2+
, were 
still higher than those generated with Mg
2+
. However, results with Ca
2+
, a hard metal, 
were markedly different. The initial velocity of DNA cleavage in the presence of Ca
2+
 
was 1–2 orders of magnitude slower than that seen with Mg
2+
. Similar results were found 
using a different matched pair of O–P and S–P substrates (site 1 oligonucleotide; data not 
shown).  
 The precipitous drop in Ca
2+
-supported cleavage of the S–P, as compared to the O–P 
substrate, together with the maintenance of high DNA cleavage rates and levels with 
Mn
2+
 and Co
2+
, strongly suggest that there is an important interaction between the metal 
ion and the 3’-bridging atom of the scissile bond in the active site of human 
topoisomerase II.  
 In order to investigate this interaction in greater detail, rates of DNA cleavage with 
both the O–P and S–P substrates were compared. Since wild-type substrates attain a 
cleavage-ligation equilibrium too quickly to ascertain rates in bench top experiments, a 
rapid chemical quench system was employed. Unfortunately, over the course of these 
assays (0–3 s), the low levels of cleavage with wild-type O–P oligonucleotides with some 
cations made the rate constants less reliable. Therefore, a nick was introduced at the 
scissile bond on the opposite strand from the one being monitored. As discussed in 
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Figure 28:  Cleavage of oligonucleotide substrates mediated by human topoisomerase II 
in the presence of different divalent metal ions. Results for wild-type (O–P, T/BO*, left) 
and phosphorothiolate (S–P, T/BS*, right) substrates are shown. The asterisk denotes the 
5’-end-labeled strand. The wild-type duplex containing an O-P scissile bond (subscript 
O) is denoted by T/BO* for the labeled bottom strand. The phosphorothiolate substrate 
containing an S-P scissile bond (subscript S) is denoted by T/BS* for the labeled 
phosphorothiolate bottom strand. DNA cleavage was carried out in the presence of 5 mM 
Mg
2+
 (closed square), Mn
2+
 (closed circle), Ca
2+
 (open square), or Co
2+
 (open circle). The 
cleavage sequence (site 2) is depicted above the graphs with the scissile bonds denoted on 
the top and bottom strands by arrows. “S” on the bottom strand denotes the location of 
the phosphorothiolate modification. Error bars represent the standard deviation of at least 
three independent experiments. 
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 Chapter III, these nicked oligonucleotides do not act as “suicide substrates,” and rapidly 
reach a cleavage-ligation equilibrium when opposite an O–P scissile bond. However, they 
maintain ~10–fold higher levels of cleavage complexes at equilibrium (Figure 10).  
 As a prelude to rapid quench experiments, bench top assays were carried out with 
these nicked substrates. Results were similar to those obtained with the corresponding un-
nicked oligonucleotides (Figure 29). Accordingly, Mn
2+
, Ca
2+
, and Co
2+
 all supported 
higher levels of DNA cleavage than Mg
2+
 with the O–P substrate (Figure 29, left panel). 
Furthermore, rates and levels of cleavage observed in the presence of Mn
2+
 and Co
2+
 
were higher than those generated with Mg
2+
 using the S–P substrate, and the initial 
velocity of DNA cleavage supported by Ca
2+
 was >10 times slower than that seen with 
Mg
2+
 (Figure 29, right panel). Once again, these findings support the conclusion that the 
divalent metal ion interacts with the bridging atom of the scissile bond and promotes the 
DNA cleavage reaction of topoisomerase II. 
 Rapid quench kinetic data for the cleavage of the O–P and S–P substrates are shown 
in Figure 30. The earliest time point that could be monitored was 5 ms, and reactions 
were followed up to 3 s. The data were best fit using a double exponential rate equation. 
The mechanistic basis for this fit is unclear at the present time (see Chapter III). 
 Although DNA cleavage levels in the presence of Co
2+
 and Ca
2+
 ultimately were as 
high or higher than observed with Mg
2+
 and the nicked O–P substrate, reaction velocities 
at the earliest time points were somewhat slower (left panel). Consequently, rate 
constants calculated for these divalent metal ions were ~0.77 and 0.050 relative to that 
derived for Mg
2+
 (Table 1). In contrast, the calculated rate constant for Mn
2+
 was ~1.3 
times greater than that for Mg
2+
. 
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Figure 29: Cleavage of nicked oligonucleotide substrates by topoisomerase II in the 
presence of different divalent metal ions. The nick is located at the scissile bond on the 
unlabeled strand (-1/+1 position). Results for the O–P (TN-1/+1/BO*, left) and S–P (T N-
1/+1/BS*, right) nicked substrates are shown. DNA cleavage was carried out in the 
presence of 5 mM Mg
2+
 (closed square), Mn
2+
 (closed circle), Ca
2+
 (open square), or Co
2+
 
(open circle). The cleavage sequence (site 2) is depicted above the graphs with the 
scissile bonds denoted on the top and bottom strands by arrows. “N” on the top strand 
denotes the location of the single-stranded nick, and “S” on the bottom strand denotes the 
location of the phosphorothiolate modification. Error bars represent the standard 
deviation of at least three independent experiments. 
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Figure 30: Pre-equilibrium cleavage of nicked oligonucleotide substrates by 
topoisomerase II in the presence of different divalent metal ions. Reaction times varied 
from 5 ms to 3 s. Results for the O–P (TN-1/+1/BO*, left) and S–P (TN-1/+1/BS*, right) 
nicked substrates are shown. The nick was located at the scissile bond on the unlabeled 
strand (-1/+1 position, see Figure 29). DNA cleavage was carried out in the presence of 5 
mM Mg
2+
 (closed square), Mn
2+
 (closed circle), Ca
2+
 (open square), or Co
2+
 (open circle). 
A double exponential curve is plotted for each reaction. The inset in the left panel shows 
reaction times up to 300 ms. Error bars represent the standard deviation of at least three 
independent experiments. 
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Table 1. Observed double exponential rate constants for metal ion-promoted DNA 
cleavage mediated by human topoisomerase II 
 
N.D., not determined 
a
Wild type, O-P; 3’-bridging phosphorothiolate, S-P; and racemic non-bridging 
phosphorothioate, RP/SP. 
b
Included in parenthesis is the relative observed rate constant compared to the value for 
Mg
2+
 (kobs/kobs Mg
2+
). 
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 Results with the nicked S–P oligonucleotide (Figure 30, right panel) paralleled those 
seen in bench top experiments. Relative to the rate constant derived for Mg
2+
, those for 
the thiophilic divalent cations, Mn
2+
 and Co
2+
, were ~6.8x107 and 3.5x106 times greater, 
respectively (Table 1). Conversely, rates for Ca
2+
-supported reactions were so low that a 
rate constant could not be calculated. As above, these data indicate that the metal ion 
interacts with the bridging atom of the scissile bond and that this interaction is important 
for the DNA cleavage event mediated by topoisomerase II. 
 
Divalent Metal Ion Interactions with the Non-bridging Atom of the Scissile Phosphate 
 Interactions between a metal ion and the non-bridging oxygen atom of the scissile 
phosphate have been observed or postulated for a number of enzymes that cleave or join 
nucleic acids (68,189,192,200,214). In order to determine whether such an interaction 
takes place in the active site of human topoisomerase II, a racemic phosphorothioate 
substrate (site 2 oligonucleotide) that substituted a sulfur atom for either the RP or SP non-
bridging oxygen atom of the scissile phosphate was employed. The first experiment was 
carried out on the bench top and monitored DNA cleavage with an un-nicked 
oligonucleotide (Figure 31). Results were similar to those observed in Figure 28 for the 
wild-type substrate that contained no sulfur atoms. It is notable that non-bridging 
phosphorothiolates also have little effect on levels of DNA cleavage mediated by E. coli 
gyrase (218). 
 The second experiment utilized the rapid quench kinetic system in conjunction with 
a nicked phosphorothioate substrate to generate rate constants for DNA cleavage 
supported by the four divalent cations (Figure 32). Once again, results were similar to 
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Figure 31: Cleavage of an oligonucleotide substrate containing a non-bridging 
phosphorothioate by topoisomerase II in the presence of different divalent metal ions. 
Reactions included a racemic mixture of phosphorothioate substrates in which the non-
bridging oxygen atoms at the scissile phosphate on the labeled strand were replaced by 
sulfur atoms. DNA cleavage was carried out in the presence of 5 mM Mg
2+
 (closed 
square), Mn
2+
 (closed circle), Ca
2+
 (open square), or Co
2+
 (open circle). Error bars 
represent the standard deviation of at least three independent experiments. 
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Figure 32: Pre-equilibrium cleavage of a nicked oligonucleotide substrate containing a 
non-bridging phosphorothioate by topoisomerase II in the presence of different divalent 
metal ions. Reaction times varied from 5 ms to 3 s. The substrate is the same as used in 
Figure 31 except that there is a nick at the scissile bond of the unlabeled strand (-1/+1 
position). DNA cleavage was carried out in the presence of 5 mM Mg
2+
 (closed square), 
Mn
2+
 (closed circle), Ca
2+
 (open square), or Co
2+
 (open circle). A double exponential 
curve is plotted for each reaction. Error bars represent the standard deviation of at least 
three independent experiments. 
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those calculated with the nicked O–P oligonucleotide (Table 1). Relative to Mg
2+
, 
calculated rate constants for Mn
2+
, Co
2+
, and Ca
2+
 were ~0.66, 2.4, and 0.25, respectively.  
 The above data with the racemic phosphorothioate substrate cannot rule out an 
interaction between a divalent cation and one of the non-bridging oxygen atoms of the 
scissile phosphate. However, if such an interaction exists in the active site of 
topoisomerase II, its effect on the DNA cleavage reaction of the enzyme appears to be 
equivocal.  
 
Human Topoisomerase II Uses Two Divalent Metal Ions for DNA Cleavage 
 A number of nucleic acid enzymes, including polymerases, nucleases, ribozymes, 
and DNA gyrase have been postulated to use two divalent metal ions in their active sites 
(190,191,193,194,196-198,200-207). In the case of most protein-based enzymes, 
evidence comes primarily from crystallographic studies and the kinetic analysis of mutant 
enzymes in which amino acids that interact with active site metal ions are altered 
(68,189,190,192,196,197,200,201). This latter approach was used with DNA gyrase (68). 
In the case of ribozymes and the 3’–>5’ exonuclease activity of E. coli DNA polymerase 
I, strong evidence for the use of two metal ions comes from kinetic analysis of RNA 
sequences that replaced oxygen atoms of the scissile phosphate with sulfur atoms 
(191,198,208-213). We employed this latter strategy to determine whether human 
topoisomerase II utilizes one or two divalent metal ions during its DNA cleavage 
reaction. 
 As a first approach, a cleavage substrate (shown in Figure 33) was used that 
contained a 3’-bridging phosphorothiolate located one base 3’ (+1/+2 position) to the 
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Figure 33: Cleavage of a phosphorothiolate linkage that is located one base 3’ to the 
intrinsic scissile bond. DNA cleavage levels were quantified at both the original O–P 
scissile bond (-1/+1, O-P, left) and the S–P bond (+1/+2, S-P, right). The sequence  (site 
1b) is shown above the graphs, and the location of the wild-type scissile bond (“O”) and 
the phosphorothiolate bond (“S”) are denoted. Reactions included Mg
2+
, Ca
2+
, or Mn
2+
 
alone, as well as mixtures of Mg
2+
 and Mn
2+
, or Ca
2+
 and Mn
2+
. All reactions had a total 
divalent cation concentration of 5 mM (2.5 mM of each divalent cation for reactions with 
two different divalent cations). Results shown are for a 30 min time point. Error bars 
represent the standard deviation of at least three independent experiments. 
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normal scissile bond (-1/+1 position). Site 1b, as opposed to site 2, was employed for this 
study because it contained a thymine residue at the +1 position. Due to the chemistry 
involved in generating the 3’-bridging phosphorothioamidite, only modified thymines 
were available. 
 DNA cleavage mediated by topoisomerase II was monitored simultaneously at the 
normal (-1/+1) O–P scissile bond as well as the off-site (+1/+2) S–P bond. Since these 
bonds are adjacent to one another, the enzyme is forced to choose between the two sites.  
 Mg
2+
, Ca
2+
, and Mn
2+
 were used for these experiments. Time courses for cleavage 
were followed up to 30 min. Data for the 30 min time point are displayed in Figure 33. 
Results for cleavage at the normal O–P scissile bond are shown in the left panel. 
Consistent with the data from Figure 28, 5 mM Mn
2+
 supported higher levels of DNA 
scission than either Mg
2+
 or Ca
2+
. A mixture (2.5 mM + 2.5 mM) of Mg
2+
 and Mn
2+
 
produced levels of DNA cleavage that were similar to that of 5 mM Mn
2+
 alone. 
However, the corresponding mixture of Ca
2+
 and Mn
2+
 supported cleavage that was ~1.7 
times greater than that seen with Mn
2+
 alone. This result suggests that topoisomerase II 
may utilize two divalent metal ions in its cleavage reaction. 
 More dramatic results were seen at the off-site bond (Figure 33, right panel). Of the 
three divalent cations employed, only 5 mM Mn
2+
 was able to support efficient cleavage 
at the +1/+2 S–P site. This probably is due to the fact that Mn
2+
 is considerably softer 
then either Mg
2+
 or Ca
2+
 (192,195,198,208-212), and is therefore able to alter the 
cleavage specificity of topoisomerase II in the presence of a 3’-bridging sulfur. Mixtures 
(2.5 mM + 2.5 mM) of Mg
2+
 + Mn
2+
 or Ca
2+
 + Mn
2+
 resulted in levels of cleavage that 
were ~1.7– or 2.2–fold higher than observed with 5 mM Mn
2+
 alone. As above, this 
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finding argues for the use of two divalent metal ions in the active site of topoisomerase 
II.  
 In light of the above results, two additional approaches were employed to further 
explore whether two metal ions are involved in catalysis. In the first, DNA cleavage was 
monitored over a range of divalent cation concentrations. These experiments utilized the 
site 2 substrate that contained a nick at the scissile bond (–1/+1 position) on the opposite 
strand. As discussed earlier, this substrate generates higher levels of DNA cleavage than 
observed with the fully wild-type oligonucleotide. Mn
2+
 (a soft cation) and Ca
2+
 (a hard 
cation) were used for these studies. As seen in Figure 34, the concentration of Mn
2+
 that 
was required to promote DNA scission mediated by topoisomerase II was considerably 
lower than that seen with Ca
2+
.  
 When cleavage of the O–P oligonucleotide was monitored (Figure 34, left panel), 
both divalent cations displayed a biphasic concentration dependence. In addition, the 
initial phase that was seen with Ca
2+
 was more pronounced than observed with Mn
2+
. 
When cleavage of the S–P oligonucleotide was monitored (Figure 34, middle panel), the 
opposite was seen. While the initial phase observed with Mn
2+
 became more prominent, 
that with Ca
2+
 essentially disappeared. The biphasic metal ion concentration dependence 
implies that there are two divalent cation sites in the DNA cleavage-ligation site of 
topoisomerase II and that both need to be filled in order to support scission. The finding 
that the initial (i.e., high affinity) phase with the S–P substrate became more prominent 
with the softer metal ion (Mn
2+
) and was lost with the harder metal ion (Ca
2+
), suggests 
that the first site that is filled by the divalent cation is the one that interacts with the 
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Figure 34: Cation concentration dependence for DNA cleavage of wild-type, 
phosphorothiolate, and phosphorothioate substrates by topoisomerase II. Results for the 
nicked (-1/+1 position) O–P (Wild-Type, left), S–P (3’-Bridging, middle), and 
phosphorothioate substrate (Non-Bridging, right) are shown. Left panel, Mn
2+
 (yellow 
squares) or Ca
2+
 (red squares) were titrated from 10 μM to 10 mM. Reactions were 
incubated for 30 min prior to stopping the reaction. The inset shows DNA cleavage at 
concentrations up to 100 μM. Middle panel, Mn2+ (yellow squares) or Ca2+ (red squares) 
were titrated from 1 μM (for Mn2+) or 10 μM (for Ca2+) to 10 mM. Reactions were 
incubated for 30 min prior to stopping the reaction. The inset shows concentrations up to 
50 μM. Right panel, Mn2+ (yellow squares) or Ca2+ (red squares) were titrated from 10 
μM to 10 mM. Reactions were incubated for 30 min prior to stopping the reaction. The 
inset shows DNA cleavage at concentrations up to 100 μM. Error bars represent the 
standard error of the mean of two independent experiments or the standard deviation of at 
least three independent experiments. 
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bridging atom of the scissile bond. Results from the non-bridging phosphorothioate 
(Figure 34, right panel) substrate were similar to that of the wild-type substrate. 
 A second approach was employed to confirm that two metal ions are required to 
support DNA cleavage mediated by human topoisomerase II. These studies took 
advantage of the enhanced affinity of Mn
2+
 and the decreased affinity of Ca
2+
 for 
substrates with 3’-bridging sulfur atoms. Experiments compared levels and rates of DNA 
scission monitored in the presence of Ca
2+
, Mn
2+
, or a combination of the two divalent 
cations. Near saturating concentrations of Ca
2+
 (5 mM and 2.5 mM with the O–P and S–P 
oligonucleotides, respectively) were paired with concentrations of Mn
2+
 that bound the 
scissile bond site without appreciably filling the second site (25 M and 5 M with the 
O–P and S–P oligonucleotides, respectively). These limiting concentrations of Mn
2+
 
supported levels of enzyme-mediated DNA cleavage that were ~10–fold lower than 
generated at the concentrations of Ca
2+
 that were used (see Figure 35). 
 Combining metal ions in reactions that utilized a wild-type or a non-bridging 
phosphorothioate substrate had little effect (Figure 35, left and right panels). Levels of 
DNA cleavage with the wild-type were only slightly higher than predicted by adding the 
amount of cleavage generated in the presence of the two individual divalent cations. This 
result was not surprising, since cleavage of the O–P bond of the site 1b oligonucleotide 
(Figure 33) was stimulated only moderately by the presence of the two metal ions. 
Similarly, levels of cleavage mediated by wild-type DNA gyrase were not enhanced in 
the presence of two different metal ions as compared to the individual cations (68). 
Stimulation of DNA cleavage by two divalent cations was observed only when residues 
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Figure 35: Cleavage of oligonucleotide substrates by topoisomerase II in the 
simultaneous presence of two different divalent metal ions. Results for the nicked (-1/+1 
position) O–P substrate (Wild-Type, left), S–P (3’-Bridging, middle), and 
phosphorothioate substrate (Non-Bridging, right) are shown. Left panel, time courses (up 
to 5 min) were carried out in the presence of 5 mM Ca
2+
 alone (red squares), 25 μM Mn2+ 
alone (yellow squares), or a mixture of 5 mM Ca
2+
 and 25 μM Mn2+ (closed squares). 
The calculated sum of the data from reactions containing Ca
2+
 or Mn
2+
 alone is also 
plotted (dashed line, “Sum”). Middle panel, time courses (up to 30 min) were carried out 
in the presence of 2.5 mM Ca
2+
 alone (red squares), 5 μM Mn2+ alone (yellow squares), 
or a mixture of 2.5 mM Ca
2+
 and 5 μM Mn2+ (closed squares). Once again, the calculated 
sum of the data from reactions containing Ca
2+
 or Mn
2+
 alone is also plotted (dashed line, 
“Sum”). Right panel, time courses (up to 30 min) were carried out in the presence of 2.5 
mM Ca
2+
 alone (red squares), 10 μM Mn2+ alone (yellow squares), or a mixture of 2.5 
mM Ca
2+
 and 10 μM Mn2+ (closed squares). The calculated sum of the data from 
reactions containing Ca
2+
 or Mn
2+
 alone is also plotted (dashed line, “Sum”). Error bars 
represent the standard deviation of three independent experiments or in some cases the 
standard error of the mean of two independent experiments. 
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 that interacted with metal ions in the active site of the prokaryotic type II enzyme were 
altered (68). 
 In contrast to results with O–P DNA, a dramatic difference was seen in reactions that 
utilized the S–P substrate (Figure 35, middle panel). The initial velocity of DNA scission 
in reactions that contained both 2.5 mM Ca
2+
 and 5 M Mn2+ (~3.5% · s-1) was nearly 40 
times faster than the calculated rate derived from the sum of cleavage observed in the 
presence of the individual metal ions (~0.09% · s
-1
).  
 In order to more fully investigate any evidence for two metal ions, a series of 
reactions with short time points and a range of Mn
2+
 concentrations were performed.  As 
seen in Figure 36, results with the wild-type substrate demonstrate a somewhat more-
than-additive effect in the presence of both divalent cations. This effect is more 
noticeable at 25 and 50 M Mn2+. Moreover, when the phosphorothiolate substrate was 
used in similar reactions, a much larger effect was observed (Figure 37). The significant 
enhancement in the rate and level of DNA scission (compared to calculated sums) was 
observed when 2.5 mM Ca
2+
 was combined with a range of Mn
2+
 concentrations (1–10 
M) that partially filled or saturated the high affinity scissile bond site (Figure 37). It is 
notable that once the scissile bond site was saturated with Mn
2+
 (7.5 M), the inclusion of 
higher levels of Mn
2+
 did not stimulate DNA cleavage further. Like the wild-type, results 
with the non-bridging phosphorothioate (Figure 38) also displayed evidence that the two 
metal ions together were more efficient at inducing cleavage than either of them 
separately. Taken together, these results provide strong evidence that human 
topoisomerase II utilizes two metal ions in its cleavage-ligation active site and that both 
must be present in order for the enzyme to cleave the DNA backbone. 
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Figure 36: Cleavage of nicked wild-type oligonucleotide substrates by topoisomerase II 
in the presence of divalent metal ion combinations. DNA cleavage reactions with 
topoisomerase II were carried out for 15, 30 or 60 s in the presence of 2.5 mM Ca2+ 
alone (red bars), 10–100 μM Mn2+ alone (yellow bars), or a mixture of 2.5 mM Ca2+ and 
10–100 μM Mn2+ (Ca2+ + Mn2+, blue bars). The calculated sum of the enzyme-mediated 
DNA cleavage from reactions containing either Ca
2+
 or Mn
2+
 alone is also shown (Sum, 
stacked open and stippled bars, respectively). All data represent the average of at least 
three independent experiments. Error bars for reactions carried out in the presence of 
Ca
2+
 + Mn
2+
 are shown. Error bars for reactions carried out in the presence of Ca
2+
 or 
Mn
2+
 alone are not shown for simplicity. 
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Figure 37: Cleavage of nicked 3’-bridging phosphorothiolate oligonucleotide substrates 
by topoisomerase II in the presence of divalent metal ion combinations. DNA cleavage 
reactions were carried out for 15, 30 or 60 s in the presence of 2.5 mM Ca
2+
 alone (red 
bars), 1–10 μM Mn2+ alone (yellow bars), or a mixture of 2.5 mM Ca2+ and 1–10 μM 
Mn
2+
 (Ca
2+
 + Mn
2+
, blue bars). The calculated sum of the enzyme-mediated DNA 
cleavage from reactions containing either Ca
2+
 or Mn
2+
 alone is also shown (Sum, 
stacked open and stippled bars, respectively). All data represent the average of at least 
three independent experiments. Error bars for reactions carried out in the presence of 
Ca
2+
 + Mn
2+
 are shown. Error bars for reactions carried out in the presence of Ca
2+
 or 
Mn
2+
 alone are not shown for simplicity. However, the standard deviation for these latter 
reactions never exceeded 1.7%. 
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Figure 38: Cleavage of nicked non-bridging phosphorothioate oligonucleotide substrates 
by topoisomerase II in the presence of divalent metal ion combinations. DNA cleavage 
reactions with topoisomerase II were carried out for 15, 30 or 60 s in the presence of 2.5 
mM Ca
2+
 alone (red bars), 10–100 μM Mn2+ alone (yellow bars), or a mixture of 2.5 mM 
Ca
2+
 and 10–100 μM Mn2+ (Ca2+ + Mn2+, blue bars). The calculated sum of the enzyme-
mediated DNA cleavage from reactions containing either Ca
2+
 or Mn
2+
 alone is also 
shown (Sum, stacked open and stippled bars, respectively). All data represent the average 
of at least three independent experiments. Error bars for reactions carried out in the 
presence of Ca
2+
 + Mn
2+
 are shown. Error bars for reactions carried out in the presence of 
Ca
2+
 or Mn
2+
 alone are not shown for simplicity. 
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Amino Acid Residues Involved in Divalent Metal Coordination in Topoisomerase II 
 Amino acids that are postulated to interact with the metal ions in the active site of 
topoisomerase II are D541, D543, D545, and E461. These assignments are based on 
previous enzymological studies of altered E. coli gyrase proteins in which homologous 
residues were mutated (68), as well as structural studies of prokaryotic topoisomerase III, 
primase (dnaG), and other DNA enzymes that contain the Toprim domain (66,219,220). 
Moreover, these assignments are consistent with a recent crystal structure of the yeast 
topoisomerase II catalytic core in a complex with nicked DNA (65). In this structure, 
residues homologous to D541, D543, and E461 of the human enzyme were in close 
proximity to the observed Mg
2+
 atom. However, as noted earlier, the yeast topoisomerase 
II-DNA complex was non-covalent in nature and the active site tyrosine was too far away 
from the scissile bond to promote cleavage.  
 To address the validity of these assignments in the human enzyme, all three Asp 
residues (D541, D543, and D545) and the Glu residue (E461) were individually mutated 
to either Ala or Cys. Each of these mutant enzymes was purified and characterization has 
begun. As seen in figure 39, compared to the wild-type human topoisomerase II, levels 
of cleavage in the presence of a wild-type substrate are dramatically reduced for all of the 
mutant enzymes. Mutations at D545 and E461 result in enzymes that display almost no 
cleavage activity with the wild-type substrate. Mutations at D543 and D541 still display 
some activity but tend to cleave more efficiently in the presence of Mg
2+
 or Ca
2+
 than 
Mn
2+
. Further, the ability to cut the phosphorothiolate is significantly reduced in all cases, 
except D543C, which retains considerable activity (Figure 40). It is interesting to note 
again that both E461 mutations display very little activity again, while D545C and  
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Figure 39: Cleavage of a wild-type substrate mediated by human topoisomerase II point 
mutants. The nicked wild-type site 2 substrate was cleaved in the presence of 5 mM Mg
2+
 
(red bars), Mn
2+
 (green bars), or Ca
2+
 (blue bars) with wild-type (WT), D545C, D545A, 
D543C, D543A, D541C, D541A, E461C, or E461A human topoisomerase II. Error bars 
represent the standard error of the mean of two independent experiments or the standard 
deviation of three independent experiments. 
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Figure 40: Cleavage of a 3’-bridging phosphorothiolate substrate mediated by human 
topoisomerase II point mutants. The nicked 3’-bridging phosphorothiolate site 2 
substrate was cleaved in the presence of 5 mM Mg
2+
 (red bars), Mn
2+
 (green bars), or 
Ca
2+
 (blue bars) with wild-type (WT), D545C, D545A, D543C, D543A, D541C, D541A, 
E461C, or E461A human topoisomerase II. Error bars represent the standard error of the 
mean of two independent experiments or the standard deviation of three independent 
experiments. 
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D545A cleave the phosphorothiolate efficiently only in the presence Mn
2+
. In fact, both 
D543C and D541C show a significant “rescue effect” when Mn
2+
 is used as the divalent 
cation in the reaction. When D543A and D541A are compared with the Cys mutations at 
those positions, cleavage levels are generally lower for the Ala mutations, especially in 
the presence of Mn
2+
 (except for D543A in the presence of Ca
2+
). Results with the non-
bridging phosphorothioate substrate (Figure 41) were similar to those seen with the wild-
type substrate. In all cases, phosphorothioate cleavage was reduced compared to the wild-
type enzyme, and the mutations at D543 and D541 maintained the highest levels of DNA 
cleavage. 
 
Conclusions 
 A model for the role of the divalent metal ion in the DNA cleavage reaction of 
human topoisomerase II is proposed in Figure 42. Our model for topoisomerase II has 
two salient features. The first is a critical interaction between one of the divalent metal 
ions and the 3’-bridging atom of the scissile phosphate. This interaction greatly 
accelerates rates of enzyme-mediated DNA cleavage and most likely is needed to 
stabilize the leaving 3’-oxygen. While kinetic studies cannot rule out an interaction 
between a metal ion and the non-bridging atoms of the scissile phosphate, such an 
interaction (if it exists) does not appear to have a major effect on rates of DNA scission.  
 The other important feature is a requirement for a second divalent metal ion in the 
DNA cleavage-ligation active site of the human type II enzyme. Although our data 
provide strong evidence for the presence of this second metal ion, they offer no direct 
insight into the specific role that it plays during DNA scission. However, based on a 
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Figure 41: Cleavage of a non-bridging phosphorothioate substrate mediated by human 
topoisomerase II point mutants. The nicked nonbridging phosphorothioate site 2 
substrate was cleaved in the presence of 5 mM Mg
2+
 (red bars), Mn
2+
 (green bars), or 
Ca
2+
 (blue bars) with wild-type (WT), D545C, D545A, D543C, D543A, D541C, D541A, 
E461C, or E461A human topoisomerase II. Error bars represent the standard error of the 
mean of two independent experiments or the standard deviation of three independent 
experiments. 
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Figure 42: A two-metal ion model for DNA cleavage by human topoisomerase II. 
Details are described in the text. Amino acids that are postulated to interact with the 
metal ions in the active site of topoisomerase II are D541, D543, D545, and E461. 
Corresponding amino acids in the A subunit of E. coli DNA gyrase are shown for 
comparison. The model postulates that one of the metal ions (left, shown in red) makes 
a critical interaction with the 3’-bridging atom of the scissile phosphate (bond shown in 
blue), which most likely is needed to stabilize the leaving 3’-oxygen (shown in green). 
While a second metal ion (right, shown in red) is required for DNA scission, our data 
provide no direct insight into its specific role during cleavage. However, based on a 
model proposed for E. coli DNA gyrase (68), this divalent cation may stabilize the DNA 
transition state and/or help deprotonate the active site tyrosine (Y805). Finally, if an 
interaction between one of the metal ions (or both) and the non-bridging atoms of the 
scissile phosphate exists, it does not appear to have a major effect on rates of DNA 
scission. The figure was adapted from Ref. (68). 
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model proposed for E. coli DNA gyrase (68), we postulate that this divalent cation may 
stabilize the DNA transition state and/or help deprotonate the active site tyrosine (Y805). 
 The mutant enzyme evidence with the phosphorothiolate substrate supports the 
model shown in Figure 42 in several ways. First, “rescue” of cleavage activity in the 
specifically presence of Mn
2+
 suggests that D545 interacts with a metal ion that 
coordinates with the 3’-bridging position during scission. A similar conclusion can be 
reached for D543 when comparing the activity of the Cys mutation with that of the Ala 
mutation, which is much lower in the presence of Mg
2+
 or Mn
2+
. Second, the lack of 
activity in the presence of the E461 mutations supports the model that this position may 
contact both of the divalent cations, making it essential to scission. Third, mutations at 
D541 also dramatically reduce activity but do not eliminate it, which might be expected if 
this position is not the only residue coordinating to the metal ion. 
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CHAPTER VI 
 
USE OF DIVALENT METAL IONS IN THE DNA CLEAVAGE REACTION OF 
HUMAN TOPOISOMERASE II 
 
 
Introduction 
 Humans encode two isoforms of the type II topoisomerase: topoisomerase II and 
II (5,8,22,42). As discussed in Chapter I, these isoforms differ in their protomer 
molecular masses, are encoded by separate genes, and display distinct physiology 
(8,10,22,42). Despite the distinct expression patterns and cellular roles of the two 
isoforms, topoisomerase II and II display a high degree (~70%) of amino acid 
sequence identity and often show similar enzymological characteristics (10,22,42). 
However, numerous studies of enzyme-mediated DNA cleavage and ligation suggest that 
there are significant (but subtle) differences in the active sites of topoisomerase II and 
II. 
 First, the DNA cleavage specificities of the two isoforms are similar, but not 
identical (63,115,221). Second, some anticancer drugs that enhance topoisomerase II-
mediated DNA cleavage display preferential effects on one isoform or the other 
(101,115,222). Third, covalent topoisomerase II-cleaved DNA complexes (i.e., cleavage 
complexes) that are formed during scission generally persist longer than equivalent 
complexes with topoisomerase II (222,223). Fourth, topoisomerase II is more sensitive 
than topoisomerase II to alterations in the scissile bond of DNA. For example, 
topoisomerase II is less able to cleave a DNA substrate that contains a 3’-bridging sulfur 
atom (i.e., phosphorothiolate) in place of the normal oxygen atom (Figure 11). It also 
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ligates a nick that has been activated by the addition of a 5’-pnitrophenyl group more 
slowly (169). 
 All type II topoisomerases require a divalent metal ion in order to cleave and ligate 
DNA. In the previous chapter, it was shown that human topoisomerase II utilized a two-
metal-ion mechanism similar to that used by primases, some DNA polymerases, and 
bacterial DNA gyrase (68,189,192,224). Given the differences in the active sites of 
topoisomerase II and II, we wanted to determine whether the two isoforms used 
divalent metal ions in a similar manner. Results indicate that topoisomerase II also 
utilizes a two-metal-ion mechanism for DNA cleavage. Furthermore, they provide the 
first kinetic evidence for an important interaction between a divalent metal ion and the 
non-bridging atom of the scissile phosphate in the DNA cleavage reaction of type II 
topoisomerases. Please note: Amber M. Burch, a Vanderbilt Summer Science Academy 
Student, started this project under my direct supervision. Consequently, Ms. Burch 
generated some of the data presented in this Chapter. 
  
Results and Discussion 
 
Interactions Between Divalent Metal Ions and Scissile Phosphate Atoms During DNA 
Cleavage Mediated by Topoisomerase II  
 
 As a first step towards defining the requirement for a divalent metal ion in the DNA 
cleavage reaction of human topoisomerase II, interactions between the cation and the 
scissile phosphate atoms were assessed. All DNA cleavage substrates utilized in the 
present study had the same sequence. However, experiments took advantage of three 
alterations in the scissile bonds of these oligonucleotides. First, all substrates contained a 
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nick at the scissile bond on the strand that was not being monitored for cleavage. As 
described for topoisomerase II in Chapter V, the presence of this nick on the opposite 
strand greatly enhances the sensitivity of the DNA cleavage reaction, stimulating both 
rates and levels of scission ~10–fold.  
 Second, a phosphorothiolate substrate was employed that substituted a sulfur for the 
3’-bridging oxygen atom at the scissile phosphate (i.e., S–P scissile bond). 
Topoisomerase II cleaved these oligonucleotides with all of the characteristics of wild-
type substrates, with the following exception: since the resulting 3’-terminal –SH moiety 
is a poor nucleophile at phosphorous (153,171), the 3’-bridging phosphorothiolate did not 
support ligation (data not shown). Thus, as described in Chapter III for topoisomerase 
II, S–P substrates isolate the forward DNA scission event from ligation, allowing high 
levels of cleavage complexes to accumulate.  
 Third, a substrate was utilized that substituted a sulfur atom for the non-bridging 
oxygen at the scissile phosphate. This phosphorothioate substrate was a racemic mixture 
that replaced either the RP or SP non-bridging oxygen atom with a sulfur atom. In contrast 
to the 3’-bridging phosphorothiolate oligonucleotide, the non-bridging phosphorothioate 
substrate maintained a DNA cleavage-ligation equilibrium and cleavage complexes did 
not accumulate over time.  
 Interactions between divalent cations and the scissile phosphate atoms were 
determined by comparing the ability of topoisomerase II to cleave DNA substrates 
containing an oxygen atom or a sulfur atom at the 3’-bridging or non-bridging position in 
the presence of metal ions of varying  “softness” (i.e., thiophilicity). The ions used for 
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this study were Ca
2+
, Mg
2+
, and Mn
2+
. As discussed in Chapter V, Mn
2+
 is the “softest,” 
or most thiophilic metal, and Mg
2+
 and Ca
2+
 are harder, or less thiophilic (215-217).  
 The first set of experiments established the ability of divalent metal ions to support 
cleavage of a wild-type O–P substrate by topoisomerase II. Consistent with previous 
work with topoisomerase II, Mn2+ and Ca2+ generated higher levels of DNA cleavage 
than Mg
2+
 (Figure 43, top left panel). Levels of cleavage complexes formed in the 
presence of Mn
2+
 or Ca
2+
 were ~5 or 2 times higher, respectively than those observed 
with Mg
2+
. Despite the low equilibrium levels of cleavage seen with Mg
2+
, initial rates of 
scission (determined by rapid chemical quench over the first seconds of the cleavage 
reaction) with the divalent cation were comparable to those generated in the presence of 
Mn
2+
 (top right panel). 
 The previous chapter demonstrated that there is an important interaction between the 
metal ion and the 3’-bridging atom of the scissile bond in the active site of human 
topoisomerase II that significantly enhances the ability of the enzyme to cleave DNA. 
Therefore, a second set of experiments examined the divalent cation preference for 
cleavage of the 3’-bridging S–P (phosphorothiolate) oligonucleotide by topoisomerase II 
(Figure 43, middle panels). Levels and rates of cleavage observed in the presence of the 
thiophilic metal ion, Mn
2+
, were considerably higher than those generated with the hard 
metal, Ca
2+
. Both the levels and rate of cleavage for reactions that contained Ca
2+
 fell 
significantly below those with Mg
2+
. The drop in Ca
2+
-supported scission of the S–P, as 
compared to the O–P DNA substrate, together with the relative rise in cleavage levels and 
rates with Mn
2+
, strongly suggest that the divalent cation contacts the 3’-bridging atom of 
the scissile bond in the active site of human topoisomerase II. Furthermore, like 
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Figure 43: Cleavage of nicked oligonucleotide substrates by topoisomerase II in the 
presence of different divalent metal ions. The nick is located at the scissile bond on the 
unlabeled strand. Thirty-minute time courses (left panels) and rapid quench time points 
(right panels) for the wild-type (top), 3’-bridging phosphorothiolate (middle), and non-
bridging phosphorothioate (bottom) are shown. DNA cleavage was carried out in the 
presence of 5 mM Mg
2+
 (closed square), Ca
2+
 (open square), and Mn
2+
 (closed circle). 
Rapid quench results for 0.5, 1, and 3 seconds are shown in the presence of Mg
2+
 (black 
bars), Ca
2+
 (open bars), and Mn
2+
 (gray bars). Error bars represent the standard deviation 
of at least three independent experiments. 
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topoisomerase II, this metal ion-DNA interaction mediated by topoisomerase II 
stimulates rates of enzyme-mediated scission. 
 Models proposed for the active site geometry of E. coli DNA gyrase (68) and human 
topoisomerase II (Figure 42) both postulate interactions between divalent metal ions and 
a non-bridging oxygen atom of the scissile phosphate. However, no direct evidence 
supporting this interaction has been reported. To this point, replacement of non-bridging 
oxygen atoms with sulfur had little effect on levels of DNA scission generated by either 
enzyme (218) [Figure 31]. Thus, it was concluded that if these postulated interactions 
between metal ions and non-bridging oxygen atoms exist, their effects on DNA cleavage 
mediated by these enzymes were equivocal.  
 Based on mutagenesis studies, it has been proposed that topoisomerase II utilizes 
divalent cations in a manner similar to that of DNA gyrase (225,226). Nonetheless, a 
third set of experiments was carried out to determine whether interactions could be 
observed between the metal ion and a non-bridging atom of the scissile phosphate in the 
active site of human topoisomerase II.  
 In marked contrast to the findings with DNA gyrase (218) and topoisomerase II 
(Chapter V), dramatic differences were seen with a substrate that contained a sulfur atom 
in the non-bridging position (Figure 43, bottom panels). Levels of cleavage generated by 
topoisomerase II in the presence of Mn2+ were ~8–fold higher than those seen with 
Mg
2+
, and rates of scission were 2 to 3 times faster. Furthermore, levels and rates of 
cleavage for reactions that contained Ca
2+
 dropped below those observed with Mg
2+
. 
Finally, as compared to results with the wild-type substrate (top panel), substitution of 
sulfur at the non-bridging position increased cleavage ~2–fold in the presence of Mn
2+
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and decreased it ~3–fold in the presence of Ca
2+
. These results provide the first evidence 
for an interaction between the divalent metal ion and a non-bridging atom of the scissile 
phosphate for any type II topoisomerase and suggest that this interaction enhances the 
ability of topoisomerase II to cleave DNA.  
  
A Two-Metal-Ion Mechanism for DNA Cleavage Mediated by Human Topoisomerase II  
 On the basis of metal ion mixing experiments, DNA gyrase and topoisomerase II 
were demonstrated to use a two-metal-ion mechanism for DNA cleavage (68) [Figure 
37]. Two approaches were utilized to determine whether human topoisomerase II uses a 
similar mechanism to mediate DNA scission. In the first, DNA cleavage was monitored 
over a range of divalent cation concentrations. These experiments utilized Mn
2+
 (a soft 
cation) and Ca
2+
 (a hard cation). As seen in Figure 44, the concentration of Mn
2+
 that was 
required to promote DNA scission mediated by topoisomerase II was considerably 
lower than that seen with Ca
2+
.  
 When cleavage of the wild-type O–P oligonucleotide was monitored (Figure 44, top 
panels), both divalent cations displayed a mild biphasic concentration dependence. This 
finding suggests that topoisomerase II utilizes more than one divalent metal ion to 
mediate DNA cleavage.  
 Introduction of a 3’-bridging phosphorothiolate had a significant effect on cation 
titrations, and resulted in a dramatically more pronounced initial phase with Mn
2+
 (Figure 
44, middle panels). This biphasic metal ion concentration dependence suggests that there 
are two divalent cation sites in the DNA cleavage-ligation domain of topoisomerase II 
and that both need to be filled in order to support scission. The finding that the initial 
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Figure 44: Metal ion concentration dependence for DNA cleavage of nicked wild-type, 
phosphorothiolate, and phosphorothioate substrates by topoisomerase II. Results for the 
wild-type (top), 3’-bridging phosphorothiolate (middle), and non-bridging 
phosphorothioate (bottom) are shown. Left panels, Mn
2+
 (closed circles) or Ca
2+
 (open 
squares) were titrated from 10 μM to 10 mM for wild-type, 1 μM to 10 mM for 3’-
bridging substrates, or 5 μM to 10 mM for non-bridging. Right panels, expanded DNA 
cleavage at concentrations up to 100 μM for wild-type and non-bridging substrates or 50 
μM for the 3’-bridging substrate are shown. All reactions were incubated for 30 min prior 
to stopping the reaction. Error bars represent the standard error of the mean of two 
independent experiments or the standard deviation of at least three independent 
experiments. 
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(i.e., high affinity) phase with the 3’-bridging phosphorothiolate substrate became more 
prominent with the soft metal ion (Mn
2+
) implies that the first site that is filled by the 
divalent cation is the one that interacts with the bridging atom of the scissile bond. 
 Introduction of a sulfur at the non-bridging position resulted in an ~2–fold increase 
in levels of DNA cleavage in the presence of Mn
2+
 and an ~2–fold decrease in the 
presence of Ca
2+
 (Figure 44, bottom panels) as compared to the wild-type substrate. 
Although this finding provides further evidence for an important interaction between a 
metal ion and the non-bridging atom of the scissile phosphate, no prominent initial phase 
was observed.  
 Therefore, a second approach was utilized to confirm that two metal ions are 
required for DNA cleavage mediated by human topoisomerase II. These studies took 
advantage of the enhanced scission observed for substrates that contained a sulfur atom in 
either the 3’-bridging or the non-bridging positions in the presence of Mn
2+
. Experiments 
compared levels of DNA cleavage monitored in the presence of Ca
2+
, Mn
2+
, or a 
combination of the two divalent cations. Near saturating concentrations of Ca
2+
 (5 mM) 
were paired with sub-saturating concentrations of Mn
2+
 (up to 100 M depending on the 
cleavage substrate). These limiting concentrations of Mn
2+
 supported levels of enzyme-
mediated DNA scission that were <15% of the observed maxima.  
 Figures 45-47 display results for topoisomerase II-mediated DNA cleavage of the 
wild-type, 3’-bridging phosphorothiolate, or non-bridging phosphorothioate substrate, 
respectively.  
 Combining metal ions in reactions that utilized topoisomerase II and a wild-type 
substrate had a small but discernable effect (Figure 45). Levels of DNA cleavage in  
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Figure 45: Cleavage of nicked wild-type oligonucleotide substrates by topoisomerase II 
in the presence of divalent metal ion combinations. DNA cleavage reactions with 
topoisomerase II were carried out for 15, 30 or 60 s in the presence of 5 mM  Ca2+ alone 
(red bars), 10–100 μM Mn2+ alone (yellow bars), or a mixture of 5 mM and 10–100 μM 
Mn
2+
 (Ca
2+
 + Mn
2+
, blue bars). The calculated sum of the enzyme-mediated DNA 
cleavage from reactions containing either Ca
2+
 or Mn
2+
 alone is also shown (Sum, 
stacked open and stippled bars, respectively). All data represent the average of at least 
three independent experiments. Error bars for reactions carried out in the presence of 
Ca
2+
 + Mn
2+
 are shown. Error bars for reactions carried out in the presence of Ca
2+
 or 
Mn
2+
 alone are not shown for simplicity. 
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reactions that contained both divalent cations were slightly higher (~1.5– to 2–fold) than 
predicted by summing the amount of cleavage generated in reactions that contained either 
Mn
2+
 or Ca
2+
. This result supports a two-metal-ion mechanism for DNA cleavage 
mediated by the  isoform and indicates that minor differences between the two cation 
sites can be discerned even in the presence of an unmodified substrate. 
 In contrast to the above results, a dramatic difference was seen in experiments that 
utilized the 3’-bridging S–P substrate (Figure 46). Levels of DNA scission in reactions 
that contained both Ca
2+
 and Mn
2+
 were 10 times greater than the calculated levels 
derived from the sum of cleavage observed in the presence of the individual metal ions. 
Furthermore, a large enhancement in the rate of DNA scission (compared to calculated 
sums) was observed when Ca
2+
 and Mn
2+
 were combined. It should be noted that these 
experiments used Mn
2+
 concentrations (1–10 M) that partially filled or saturated the 
high affinity scissile bond site (see Figure 44, middle panel) without appreciably filling 
the second site. These data confirm the two-metal-ion mechanism as well as the 
importance of the metal ion interaction with the 3’-bridging atom of the scissile 
phosphate. 
 As seen in Figure 47, the inclusion of a non-bridging sulfur at the scissile phosphate 
also stimulated DNA cleavage in reactions that contained a mixture of Ca
2+
 and Mn
2+
. 
Levels of cleavage in reactions that contained both metal ions were ~5 times higher than 
predicted by the calculated sums. Once again, these data confirm the two-metal-ion 
mechanism for DNA cleavage mediated by topoisomerase II, and they also validate the 
significance of the metal ion interaction with the non-bridging atom of the scissile
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Figure 46: Cleavage of nicked 3’-bridging phosphorothiolate oligonucleotide substrates 
by topoisomerase II in the presence of divalent metal ion combinations. DNA cleavage 
reactions with topoisomerase II were carried out for 15, 30 or 60 s in the presence of 5 
mM Ca
2+
 alone (red bars), 1–10 μM Mn2+ alone (yellow bars), or a mixture of 5 mM 
Ca
2+
 and 1–10 μM Mn2+ (Ca2+ + Mn2+, blue bars). The calculated sum of the enzyme-
mediated DNA cleavage from reactions containing either Ca
2+
 or Mn
2+
 alone is also 
shown (Sum, stacked open and stippled bars, respectively). All data represent the average 
of at least three independent experiments. Error bars for reactions carried out in the 
presence of Ca
2+
 + Mn
2+
 are shown. Error bars for reactions carried out in the presence of 
Ca
2+
 or Mn
2+
 alone are not shown for simplicity. 
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Figure 47: Cleavage of nicked non-bridging phosphorothioate oligonucleotide substrates 
by topoisomerase II in the presence of divalent metal ion combinations. DNA cleavage 
reactions with topoisomerase II were carried out for 15, 30 or 60 s in the presence of 5 
mM Ca
2+
 alone (red bars), 10–100 μM Mn2+ alone (yellow bars), or a mixture of 5 mM 
Ca
2+
 and 10–100 μM Mn2+ (Ca2+ + Mn2+, blue bars). The calculated sum of the enzyme-
mediated DNA cleavage from reactions containing either Ca
2+
 or Mn
2+
 alone is also 
shown (Sum, stacked open and stippled bars, respectively). All data represent the average 
of at least three independent experiments. Error bars for reactions carried out in the 
presence of Ca
2+
 + Mn
2+
 are shown. Error bars for reactions carried out in the presence of 
Ca
2+
 or Mn
2+
 alone are not shown for simplicity. 
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phosphate. It is notable that results with the non-bridging substrate were markedly 
different with topoisomerase II (Figure 38). 
 Scission levels generated by topoisomerase II in the presence of Ca2+ and Mn2+ 
were marginally higher compared to those predicted by the calculated sums (Figure 47) 
or by those observed in the presence of both divalent cations with the wild-type 
oligonucleotide (compare with Figure 45). These findings indicate that human 
topoisomerase II and II utilize divalent metal ions differently for some aspects of their 
DNA cleavage reactions. The interaction between a metal ion and the non-bridging atom 
of the scissile phosphate is important for the DNA cleavage reaction of topoisomerase II 
and substantially raises levels of scission. However, if the parallel interaction in 
topoisomerase II exists, it has little effect on DNA scission. 
 
Conclusions  
 A model for the use of divalent metal ions in the DNA cleavage reaction of human 
type II topoisomerases is proposed in Figure 48. Amino acids that are postulated to 
interact with the metal ions in the active site of topoisomerase II and II are assigned 
based on previous enzymological studies of mutated E. coli DNA gyrase and human 
topoisomerase II proteins (68,225,226), as well as structural studies of bacterial 
topoisomerase III, yeast topoisomerase II, and other DNA enzymes that contain the 
Toprim domain (65,66,219,220).  
 Our model has several features. First, topoisomerase II and II both employ a two-
metal-ion mechanism to support DNA cleavage. Second, both enzyme isoforms utilize an 
interaction between a divalent metal ion (metal ion 1) and the 3’-bridging atom of the 
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Figure 48: A two-metal-ion model for DNA cleavage by human topoisomerase II and 
II. Details are described in the text. Amino acids that are postulated to interact with the 
metal ions in the active site of both isoforms are shown. The model postulates that the 
metal ions bind to topoisomerase II in an ordered fashion, in which the binding of metal 
ion 1 (M1
2+
, shown in blue) is a prerequisite for the binding of metal ion 2 (M2
2+
, shown 
in blue). M1
2+
 makes a critical interaction with the 3’-bridging atom (left, shown in red) 
of the scissile phosphate (left, bond shown in green), which most likely is needed to 
stabilize the leaving 3’-oxygen (left, shown in red). M2
2+
 is required for DNA scission 
and likely interacts with the non-bridging oxygen (right, shown in red) during scission. 
This divalent cation may stabilize the DNA transition state and/or help deprotonate the 
active site tyrosine. While interactions between M2
2+
 and the non-bridging atom of the 
scissile phosphate significantly enhance DNA cleavage mediated by topoisomerase II, 
effects on DNA scission mediated by topoisomerase II are equivocal. The model was 
adapted from Ref. (68). 
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 scissile phosphate to accelerate rates of enzyme-mediated DNA cleavage, most likely by 
stabilizing the leaving 3’-oxygen. At the present time, it is not known whether metal ion 
1 also has interactions with the non-bridging oxygen. Third, a second metal ion (metal 
ion 2) appears to contact a non-bridging atom of the scissile phosphate in the active site 
of topoisomerase II. This interaction plays a significant role in DNA cleavage mediated 
by the  isoform and greatly stimulates scission. As proposed previously, this metal ion is 
believed to stabilize the DNA transition state and/or help deprotonate the active site 
tyrosine (68,226). Although topoisomerase II has an absolute requirement for metal ion 
2, the role of this divalent cation in its DNA cleavage reaction is unclear.  Results of the 
present study cannot rule out an interaction between the metal ion and the non-bridging 
oxygen in the active site of topoisomerase II. However, if the interaction exists, it does 
not affect rates of DNA cleavage. 
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CHAPTER VII 
 
CONCLUSIONS 
 
 Type II topoisomerases are ubiquitous enzymes that regulate the topological state 
of DNA. These enzymes are involved in a number of critical cellular processes, such as 
replication, transcription, and recombination, and are effective and commonly used 
targets for anticancer drugs. Despite their essential physiological functions, the basic 
mechanism of type II topoisomerases is not completely understood. Important questions 
concerning the mechanism of cleavage, the coordination of the two protomer subunits, 
and the role of the required divalent cations have been difficult to address. Previously, 
there were no systems established to directly tackle these challenging concepts.  The 
work described in this dissertation uses several oligonucleotide-based approaches to help 
unravel the complexities of the human isoforms of topoisomerase II.  
 
Isolation of the Forward DNA Cleavage Reaction of Topoisomerase II 
The low level of DNA cleavage at equilibrium and the tight coupling of the 
cleavage and ligation reactions have made it difficult to characterize the mechanism by 
which topoisomerase II cuts the double helix. Therefore, Chapter III of this dissertation 
describes the development of a system that isolates topoisomerase II-mediated DNA 
scission from ligation. This goal was accomplished using oligonucleotide substrates that 
contained a 3’-bridging phosphorothiolate at the scissile bond. Results demonstrate that 
the characteristics of topoisomerase II-mediated cleavage of phosphorothiolate 
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oligonucleotides were identical to those seen with wild-type substrates, except that no 
ligation was observed.  
This unidirectional accumulation of cleavage complexes provided an important 
advantage over traditional “suicide substrates” that require a time-dependent conversion 
from a reversible to an irreversible, covalent complex. As seen in Chapter III, a +2/+3 
nicked suicide substrate may leave the impression that etoposide enhances the forward 
rate of DNA cleavage. However, experiments with phosphorothiolate substrates 
demonstrate that there is no enhancement in the forward rate of scission in the presence 
of etoposide. This result is consistent with the fact that etoposide is known to strongly 
inhibit topoisomerase II-mediated DNA ligation. Results also indicate that the two 
enzyme subunits are partially coordinated and that cleavage at one scissile bond increases 
cleavage at the other. Further, abasic sites that increase levels of cleavage complexes 
without affecting ligation stimulate the forward rate of scission.  
Not only do phosphorothiolate substrates provide significant advantages over 
traditional “suicide substrates”, but they will also be valuable for future studies on DNA 
scission and the topoisomerase II-DNA cleavage complex. For example, these substrates 
currently are being used to crystallize covalent topoisomerase II-DNA complexes for 
structural studies in collaboration with Dr. James Berger, University of California at 
Berkeley.  
 
Coordination of the Two Protomer Subunits of Topoisomerase II 
 Since topoisomerase II modulates DNA topology by generating double-stranded 
breaks in DNA, the two protomer subunits must be relatively well-coordinated. As seen 
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in Chapter III, cleavage at one strand appears to increase the rate of cleavage of the 
opposite strand. These studies were extended in Chapter IV by using wild-type substrates 
in the presence or absence of scissile bond nicks. Results confirm that the presence of a 
nick at one scissile bond dramatically increases the rate of cleavage by human 
topoisomerase II at the scissile bond on the opposite strand. This enhanced rate of 
cleavage of the second strand likely coordinates the two protomer subunits of 
topoisomerase II and allows the enzyme to create double-stranded breaks. As determined 
by crystallography of yeast topoisomerase II, there is a severe bend in DNA bound in the 
active site of the enzyme. We propose that the increase in rate at the second strand is 
caused by the increased flexibility imposed by the introduction of a nick in the first 
strand. Such flexibility would allow the substrate to bend into position in the active site 
more readily. 
 It was also found that the presence of a nick on one strand induces cleavage four 
bases away on the opposite strand, even in the absence of a native cleavage site. Thus, 
nicks are topoisomerase II poisons that generate novel sites of DNA cleavage. This 
finding may have implications for the actions of type II enzymes during apoptotic DNA 
fragmentation. Moreover, it suggests a mechanism whereby topoisomerase II may impact 
the physiological effects of endogenous, environmental, or pharmaceutical compounds 
that damage the genetic material. For example, events or compounds that result in the 
generation of nicks in DNA could lead to an increase in topoisomerase II cleavage 
complexes and threaten cell survival. 
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Metal Ion Usage by Type II Topoisomerases 
 Chapters V and VI discuss the role of divalent metal ions in the DNA cleavage 
reaction of human topoisomerase II and II. First, Chapter V demonstrated that the “thio 
effect” could be used to examine metal ion usage by topoisomerase II. This work 
utilized a series of divalent metal ions with varying thiophilicities in conjunction with 
DNA cleavage substrates that substituted a sulfur atom for the 3’-bridging oxygen or the 
non-bridging oxygens of the scissile phosphate. Based on the results, we propose that 
topoisomerase II mediates DNA cleavage via a two metal ion mechanism. In this model, 
one of the metal ions makes a critical interaction with the 3’-bridging atom of the scissile 
phosphate. This interaction greatly accelerates rates of enzyme-mediated DNA cleavage, 
and most likely is needed to stabilize the leaving 3’-oxygen.  
 The model was tested further by mutagenesis of topoisomerase II. By changing 
three conserved Asp residues (D545, D543, and D541) and one Glu residue (E461) to 
either Cys or Ala, the results in Chapter V demonstrate that each of these positions 
impacts the level of DNA cleavage. These highly conserved residues are found in several 
different nucleic acid-acting enzymes that utilize metal ions in their reaction chemistry 
and are believed to function in coordinating metal ion(s) around the active site. Results 
from the mutant enzymes support the model proposed for amino acid involvement in 
topoisomerase II. It is notable that E461 is the only residue proposed in the model to 
coordinate to both metal ions and a mutation at this position to either Cys or Ala had the 
greatest effect on DNA cleavage of any of the mutations, essentially abolishing activity.  
Further work with these mutants will be needed to more fully elucidate the role of these 
interactions. 
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 As seen in Chapter VI, our work on metal ions was extended by examining the 
cleavage reaction of human topoisomerase II. The data demonstrate that similar to 
topoisomerase II, topoisomerase II employs a two-metal-ion mechanism to support 
DNA cleavage. Again, one metal ion makes an interaction with the 3’-bridging atom of 
the scissile phosphate. However, unlike the  isoform, there is an important interaction 
between a divalent second metal ion and a non-bridging atom of the scissile phosphate 
that stimulates DNA cleavage mediated by topoisomerase II. If this interaction exists in 
topoisomerase II, its effects on DNA cleavage are equivocal. This result is the first 
evidence for an interaction between a metal ion and the non-bridging position of the 
DNA during scission by a type II topoisomerase.  
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